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ABSTRACT 
Lydia Feinstein:  Implementation of Pediatric HIV Prevention and Care Guidelines in Routine 
Settings:  Outcomes Among HIV-exposed Infants in Kinshasa, Democratic Republic of Congo 
(2007-2013) 
(Under the direction of Frieda Behets) 
Outcomes of HIV-exposed infants remain inadequately studied, particularly in resource-
deprived settings.  We conducted an observational study of 1707 mother-infant pairs who 
received care in a comprehensive HIV program in Kinshasa, DR Congo during 2007-2013.  The 
study resulted in two manuscripts, one which describes temporal changes in the outcomes of 
HIV-exposed infants and one that assesses the relationship between infant retention in care and 
the provision of combination antiretroviral therapy (cART) to their HIV-infected mothers.    
The first manuscript suggests there have been encouraging improvements over time in the 
outcomes of HIV-exposed infants but that continued efforts are needed.  Accounting for 
competing risks (e.g. death), we estimated the cumulative incidences of having an initial 
specimen collected for HIV virologic testing, loss to follow-up (LTFU), HIV transmission, and 
death through age 18 months, as well as cART initiation among HIV-infected infants through 
age 24 months.  The 18-month cumulative incidence of specimen collection increased from 73% 
(95% confidence limit [CL]: 68-78%) for infants enrolled in 2007-2008 to 99% (95% CL: 98-
100%) for infants enrolled in 2011-2012. The 18-month cumulative incidence of HIV declined 
from 15% (95% CL: 11-21%) for infants enrolled in 2007-2008 to 8% (95% CL: 6-11%) for 
infants enrolled in 2011-2012 and death declined from 8% (95% CL: 5-11%) to 3% (95% CL: 2-
5%).  The 18-month cumulative incidence of LTFU did not improve, with 18-month cumulative
 iv 
incidences of 18% (95% CL: 14-22%) for infants enrolled in 2007-2008 and 18% (95% CL: 15-
21%) for infants enrolled in 2011-2012.  Among HIV-infected infants, the 24-month cumulative 
incidence of cART increased from 61% (95% CL: 43-75%) to 97% (95% CL: 82-100%); the 
median age at cART decreased from 17.9 to 9.3 months. 
In the second manuscript, we show that increasing access to cART for pregnant women 
could improve retention in care of their HIV-exposed infants.  The 18-month cumulative 
incidence of LTFU was 9% among infants whose mothers had initiated cART by infant 
enrollment and 19% among infants whose mothers had not yet initiated cART (Gray’s p-value 
<0.001). Adjusted for baseline factors, the subdistribution hazard ratio comparing LTFU between 
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CHAPTER 1:  SPECIFIC AIMS 
 
Globally, an estimated 1.4 million infants are born each year to women living with 
human immunodeficiency virus (HIV) [1].  Although the incidence of vertical HIV transmission 
is declining [1], there remain substantial gaps in the literature on outcomes of HIV-exposed 
infants and drivers of those outcomes, particularly in routine care settings.  The overall goal of 
this project was to assess implementation of HIV-exposed infant care and key outcomes in 
Kinshasa, Democratic Republic of the Congo (DRC).  We conducted a cohort study of routinely 
collected clinical data on approximately 1,700 infants who received care between January 2007 
and August 2013 in a comprehensive HIV prevention, care and treatment program affiliated with 
the University of North Carolina (UNC-DRC program).  There were two specific aims to the 
project.   
Specific Aim 1:  Describe temporal changes in the outcomes of HIV-exposed infants 
since the implementation of HIV-exposed infant care in Kinshasa.   
Guidelines for prevention of mother-to-child transmission of HIV (PMTCT) have 
developed rapidly, yet little is known about how outcomes of HIV-exposed infants have changed 
over time.  Accounting for competing risks, we estimated the cumulative incidences of early 
infant HIV diagnosis (EID), HIV transmission, death, loss to follow-up (LTFU), and 
combination antiretroviral therapy (cART) initiation for infants enrolled during three calendar 
periods (2007-2008, 2009-2010, and 2011-2012).  
  
 2 
Specific Aim 2:  Quantify the effect of providing cART to HIV-infected mothers on 
LTFU of their HIV-exposed infants.   
LTFU of HIV-exposed infants is a common problem in most PMTCT programs, with 
some studies reporting over 70% LTFU [2–11].  LTFU reduces the clinical- and population-level 
impacts of PMTCT programs [12], opportunities for EID, and the likelihood of early treatment 
initiation among HIV-infected infants.  The literature suggests that receiving cART improves 
retention among HIV-infected adults [13,14]; as such, we hypothesized that infants whose 
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CHAPTER 2:  INTRODUCTION	  
 
Section 2.1.  State of the pediatric HIV epidemic 
Over 35 million people were estimated to be living with HIV in 2012, with 
approximately 2.3 million new infections occurring each year [1].  More than three million of the 
individuals living with HIV are children under 15 years of age [2].  Over 90% of pediatric 
infections result from mother-to-child transmission during pregnancy, labor, or breastfeeding [3].  
Although PMTCT programs have been scaled-up worldwide and the incidence of vertical 
transmission is declining, an estimated 260,000 children continue to be infected with HIV each 
year [1].  Pediatric HIV has virtually been eliminated in developed countries.  Sub-Saharan 
Africa, where 90% of all pediatric HIV infections occur, carries a disproportionate burden of the 
ongoing epidemic [1].  
 
Section 2.2.  Challenges faced by HIV-exposed infants and their families 
Although there has been a reduction in the size of the pediatric HIV epidemic, a decrease 
in the number of infants exposed to HIV during pregnancy, labor, and breastfeeding has not 
occurred.  In 2012, 1.3 million infants were born to HIV-infected mothers [4].  In some 
countries, HIV-exposed infants may account for up to 30% of all births [5].  As access to 
interventions such as cART is increasing and individuals living with HIV are experiencing 
healthier and longer lives, the population of HIV-exposed infants will likely grow [6,7].   
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Regardless of whether they become infected with HIV, HIV-exposed infants face unique 
challenges compared to HIV-unexposed infants due to the social, economic, and health impacts 
HIV has on families [4].  Illness within the family may lead to or worsen already existing income 
loss, food insecurity, and lower educational attainment [4].  HIV-infected women also have an 
increased rate of adverse birth outcomes, such as preterm birth and low birth weight [8,9].  
Furthermore, HIV-exposed infants often experience the death of one or more care-givers, as 
evidenced by the world’s 18 million children who are estimated to have been orphaned due to 
HIV/AIDS [10].  
Moreover, HIV-exposed infants, even if they remain uninfected with HIV, experience 
increased morbidity and mortality early in life.  The elevated morbidity and mortality appears to 
be in large part driven by the high burden of infectious disease that has been observed in this 
population [11–15].  The reasons for the increased infectious disease burden remain unclear.  
Some evidence suggests that HIV-exposure impairs the immune system of exposed infants, 
increasing their susceptibility to infectious agents [16].  Others point to the potentially increased 
frequency of exposure to infectious agents that may occur in families affected by HIV, as well as 
to the potential effect exposure to antiretroviral therapy may have on immune function.   
 
Section 2.3.  HIV-exposed infant care in the Democratic Republic of Congo 
The HIV epidemic in the DRC is particularly unique.  The DRC is an extremely resource-
deprived setting with one of the highest burdens of maternal and child mortality in the world 
[17].  Scale-up of HIV-exposed infant care in the DRC has been extremely challenging due to 
the aftermath of decades of civil war and a deteriorating socioeconomic infrastructure.   
Although the estimated two percent prevalence of HIV among women seeking antenatal care in 
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the capitol city of Kinshasa [18] is relatively low compared to other sub-Saharan African 
settings, the most current estimate available suggests that fewer than 20% of HIV-infected 
women in the country currently have access to PMTCT services.  Although it is likely that access 
to PMTCT services has increased in recent years [19], with a population of almost 10 million 
people in Kinshasa, there is a high unmet need for quality HIV-exposed infant care.   
 
Section 2.4.  Importance of early infant diagnosis 
Compared to adults, disease progression in HIV-infected children is extremely rapid.  If 
they are not started on cART, one-third of infected infants will die within the first year of life 
and half will die within the first two years of life [20–23].  As early diagnosis is a prerequisite for 
early treatment, the World Health Organization (WHO) recommends that HIV-exposed infants 
be tested for HIV within the first four to six weeks after birth [23].  However, fewer than 15% of 
exposed infants are currently tested for HIV in the first two months of life [24,25], suggesting 
that more guidance is needed on how to operationalize current testing recommendations.   
EID of HIV-exposed infants by virological testing represented a major paradigm shift and 
has only been routinely recommended in resource-constrained settings during the past few years 
[26,27].  Before the availability of virological testing, the HIV infection status of exposed infants 
could only be confirmed by serology at 18-months of age [28,29].  The implementation of 
virological testing has allowed children infected with HIV to be identified as early as six weeks 
of age and immediately started on treatment [24,26].  However, the implementation of DNA 
PCR testing has presented new challenges, as it means that HIV-exposed infants need to be 
linked into care earlier than ever before.   
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Section 2.5.  Early infant diagnosis as a care continuum  
Although many vertically exposed infants are identified in the antenatal care and delivery 
setting through testing of HIV-infected pregnant women and new mothers, follow-up of infants 
and their mothers is poor [30–37].  Exposed infants may be referred for testing, but many 
mothers do not bring their infants for testing until they show signs or symptoms of illness and 
many never bring them at all. Several structural barriers to testing have been identified, including 
cost, distance to testing centers, limited availability of testing sites, waiting time at the clinic, and 
negative experiences with providers [35,38–40].  Such structural barriers, in conjunction with 
fatalistic attitudes towards pediatric HIV and fear of stigma and discrimination [41], have 
contributed to the low numbers of exposed infants being retained in care. 
EID is further complicated by the type of assays available for accurate testing of 
vertically exposed infants.  While rapid point-of-care tests to detect HIV antibodies are widely 
available for older children and adults, they are unreliable for use among HIV-exposed infants 
because maternal HIV antibodies can persist up to 18 months of age [24,28,29].  Antibody-based 
tests therefore only confirm HIV exposure in infants and accurate diagnosis in this population 
requires virological testing.  Deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) 
assays are the most widely available virological test for EID, but few PMTCT programs have 
laboratory capacity to process the assays onsite [42].  As such, blood samples are often collected 
and dried on filter paper (dried blood spots) so that they can be sent for testing at an external 
laboratory [42,43].  Turnaround time for specimen processing takes days in ideal conditions, but 
realistically may take months in field settings [42].  A new generation of point-of-care infant 
HIV tests have been evaluated, but are yet to be available in the field.  
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Thus, there are currently multiple steps involved in diagnosing HIV in exposed infants.  
As previously summarized by Ciaranello et al., the EID cascade includes: “infant presentation to 
care, test offer by healthcare professionals, test acceptance by parents/caregivers, specimen 
processing, result return to healthcare facilities and [result communicated to] 
parents/caregivers…” [42].  Each of these steps represents a potential loss point in the 
implementation of EID, with complete implementation depending on multiple structural- and 
individual-level factors.   
Visual depictions of the EID cascade, one of which is shown in Figure 2.1, are useful in 
conceptualizing EID as a process.  Figure 2.1 builds on the cascade published by Ciaranello et al. 
[42], except that it also includes the important requirement that infants must first access care 
before they can receive EID.  Unlike the cascade by Ciaranello et al., Figure 2.1 also points out 
the need to reconfirm positive HIV test results, as discussed in the following paragraph.  
As the last section in Figure 2.1 alludes to, complete EID generally requires more than a 
single test due to continued exposure to HIV through breastfeeding after the first test.  According 
to the WHO guidelines, there are three major HIV testing events that are supposed to occur as 
part of the EID process for children without signs or symptoms suggestive of HIV.  These 
include a first DNA PCR at four to six weeks of age, a serological test around nine months of age 
followed by a second DNA PCR test if seropositive, and a final serology at 18 months of age or 
three months after discontinuation from breastfeeding (whichever comes later) [24].  
Confirmatory DNA PCR testing is recommended for infants who test positive by DNA PCR due 
to the possibility of obtaining a false-positive result [24,44].  Additional testing by serology is 
recommended for infants with signs or symptoms suggestive of HIV, followed by a DNA PCR 
test if seropositive [24].   
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Figure 2.1 - Early infant diagnosis cascade. 
 
 
The above figure builds on the cascade presented by Ciaranello et al. [45]. 
 
  
Care accessed and HIV exposure 
determined 
Specimen sent to laboratory for 
processing 
HIV-test offered and specimen 
collected 
Results returned to healthcare facility 
and communicated to caregiver 
HIV-positive: Positive test result 
confirmed and infant linked to 
lifelong care and treatment 
HIV-negative: Infant retested 
according to guidelines and after 
discontinuation of breastfeeding 
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Continued exposure to HIV after delivery poses a substantial risk, with up to a third of 
transmissions occurring through breastfeeding [46,47].  However, the benefits of breastfeeding 
for preventing early childhood morbidity and mortality are also substantial, particularly in 
resource-deprived settings where safe formula feeding is often problematic due to unstable 
supplies and a lack of clean water [48–50].  Accordingly, the WHO recommends that HIV-
infected mothers in low- and middle- income countries breastfeed through at least 12-months of 
age, and discourages weaning for the purpose of obtaining an HIV diagnosis [23,24].  As the 
HIV testing algorithm for exposed infants is dependent on their weaning status, regular follow-
up is needed to assess their exposure through breastfeeding.   
Finally, additional visits need to occur during the EID process to provide prophylactic 
regimens such as cotrimoxazole and extended NVP, monitor the child’s health, and to provide 
other services (e.g. vaccinations).  Since it can take a month or longer to obtain the results of a 
DNA PCR test in resource-constrained settings and it is often unknown ahead of time when 
exactly the result will be available at the clinic, follow-up visits also provide crucial 
opportunities to communicate infant HIV test results to caregivers and to initiate cART among 
infants who are HIV-positive.   
 
Section 2.6.  Early infant diagnosis as part of the evolving prevention of mother-to-child 
HIV transmission landscape 
 
The EID process is best understood within the greater framework of what has been 
referred to as the “PMTCT cascade,” a series of services that begins with women accessing 
antenatal care and continues postpartum through the HIV status determination of exposed infants 
and the successful linkage of HIV-infected mothers and children to lifelong HIV care and 
treatment.  Several versions of the PMTCT cascade have been depicted and are often tailored by 
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programs to reflect particular PMTCT care protocols.  For reference, one version of the PMTCT 
cascade is shown in Figure 2.2.  Figure 2.2 builds upon the cascade published by Wettstein et al. 
[51], incorporating the new recommendation that countries adopt Option B+, as discussed in 
more detail below.  The new recommendation allows us to simplify the cascade by Wettstein et 
al. by removing the need to assess for cART eligibility before initiating pregnant women on 
cART. 
As depicted in Figure 2.2, HIV testing of exposed infants is downstream to many 
essential steps in PMTCT programming.  It is important to consider the EID process within the 
context of the greater PMTCT cascade in the evaluation of HIV-exposed infant care because, 
since the implementation of infant virological testing, other parts of the PMTCT landscape have 
also continued to evolve rapidly.  For example, in its 2010 guidelines the WHO changed its 
recommendations for the period of breastfeeding from six months to at least 12 months, which 
had major implications for the length of exposed infant care [52].  Perhaps the most rapidly 
evolving aspect of the PMTCT landscape has been the guidelines for providing antiretroviral 




Figure 2.2 - Prevention of mother-to-child HIV transmission cascade. 
 
Abbreviations:  PMTCT, prevention of mother-to-child HIV transmission; cART, combination 
antiretroviral therapy.   
The above figure builds on the the cascade presented by Wettstein et al. [51] 
Care accessed during pregnancy at a 
facility that offers PMTCT services 
HIV+ status determined (cART eligibility 
assessed or not per PMTCT strategy 
adopted) 
HIV counseling and testing provided 
cART or other PMTCT prophylactic 
regimen initiated 
Postnatal interventions provided for 
mother and infant, including evaluation, 
testing, and prophylaxis for infant  
Delivery at a PMTCT facility 
Linkage to lifelong care and treatment for 
mothers and HIV-infected infants 
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Changes in the recommendations of ARVs for PMTCT have been substantial and 
implementation has varied drastically between programs.  Commonly used PMTCT drug 
interventions include simplified short-course ARV prophylaxis for mothers during pregnancy 
and for exposed infants immediately after birth, as well as cART for immunologically or 
clinically eligible mothers [53].  In many resource-deprived settings, the only available drug 
intervention is single-dose nevirapine (NVP), which has been shown to reduce vertical HIV 
transmission to eight percent of exposed infants [54].  More effective combination regimens can 
reduce transmission to below two percent [53]. 
In its 2010 PMTCT guidelines, the WHO recommended that programs implement one of 
two regimen options for mothers not eligible for cART for their own health (i.e. maternal CD4 
count >350 cells/mm3 and WHO clinical stage I or II) and their HIV-exposed infants [52].  The 
so-called options “A” and “B” are described in detail Table 2.1 below.  Moreover, both options 
A and B include a short-course ARV regimen for cART-ineligible women starting during 
pregnancy and continuing until one week after delivery (option A) or until one week after all 
exposure to breast milk has ended (option B).   Both options also include a short-course ARV 
regimen for exposed infants starting from birth and continuing until four to six weeks of age 
(options A and B) and until one week after all exposure to breast milk has ended (option A only).  
With regards to preventing vertical transmission of HIV, they were presented by the WHO as 
equally effective options.   
In April 2012, the WHO released an update to the comprehensive 2010 guidelines in 
which it recommended cART for all pregnant women, regardless of previously established 
eligibility criteria (Option B+) [55].  As the 2010 guidelines required programs to distinguish 
between treatment and prophylaxis based on CD4 count or clinical staging criteria, the updated 
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recommendations were expected to be simpler to implement from a programmatic prospective 
while also preventing transmission to serodiscordant partners and subsequent children.   
In addition to requiring mothers and their exposed infants be linked into care earlier, the 
new PMTCT interventions require more complex follow-up and service delivery.  Although 
policy makers and program implementers have called into question the operational feasibility 
and sustainability of such efforts in resource-deprived settings, few programs have actually 
published their program’s implementation experience and clinical results.  As such, many of the 
current WHO guidelines for PMTCT, including the recent recommendation to implement 
lifelong cART for all pregnant women (option B+) in large part because of its expected 
programmatic advantage compared to short-course regimens (options A and B), are based on 
theoretical feasibility and efficacy rather than on demonstrated results in real-world PMTCT 
settings [55].   
 
  
Table 2.1 - Three strategies for prevention of mother-to-child HIV transmission. 
 Maternal regimen Infant regimen 
 cART eligible 
(CD4 <350) 
cART ineligible (CD4 <350) Breastfeeding Not breastfeeding 
Option A Lifelong cART AZT from 14 weeks gestation 
until onset of labor, single-dose 
NVP at onset of labor, and 
AZT/3TC from labor until 7 
days postpartum 
No maternal cART  Daily NVP 
from birth until the cessation of 
breastfeeding 
Maternal cART  Daily NVP from 
birth until 4-6 weeks of age 
Daily NVP from 
birth until 4-6 
weeks of age 
Option B Lifelong cART cART from 14 weeks gestation 
until delivery or 1 week after the 
cessation of breastfeeding 
Daily NVP or AZT from birth 
until 4-6 weeks of age 
Daily NVP or AZT 
from birth until 4-6 
weeks of age 
Option B+ Lifelong cART Lifelong cART Daily NVP or AZT from birth 
until 4-6 weeks of age 
Daily NVP or AZT 
from birth until 4-6 
weeks of age 
Strategies as outlined by the World Health Organization [55] 
Abbreviations: cART, combination antiretroviral therapy; AZT, zidovudine; NVP, nevirapine; 3TC, lamivudine 
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Section 2.7.  Retention and combination antiretroviral therapy 
The complex follow-up required to care for HIV-exposed infants through the care 
continuum necessitates the need to focus on retention efforts.  A crucial goal is to keep exposed 
infants in care until their final HIV status can be determined so that they can be started on 
treatment as soon as possible if a positive status is confirmed.  However, the literature indicates 
consistently high attrition from exposed infant care under a variety of programmatic settings 
[30–37].  For example, a large study of PMTCT program effectiveness in South Africa reported 
that one-third of infants never returned for a follow-up visit and that almost 70% were LTFU by 
four months of age [30].  Another study in Kenya found that seven percent of exposed infants 
were LTFU by three months of age and another 27% by 18 months of age [36].  Attrition is a 
major concern for programs attempting to scale-up PMTCT interventions because, even with the 
availability of efficacious ARV regimens, only a marginal impact on population-level vertical 
transmission can be achieved if program retention remains low [56]. 
The adult HIV literature indicates that patients receiving cART are less likely to be LTFU 
compared to patients not on cART [57,58].  Since infants are dependent on their caregivers to 
bring them to care, this evidence suggests that providing cART to caregivers may also play a role 
in the retention of their infants.  Limited evidence from two studies suggests that receiving 
maternal cART may improve the proportion of HIV-exposed infants who receive EID.  The first 
study, which included 217 mother-infant pairs from Mozambique, found that mothers who 
received cART were more likely to ever bring their infant for a virological test compared to 
women who did not receive cART, with an odds ratio of 3.15 (95% CL: 1.02-9.73) controlling 
for self-reported socio-demographic factors [59].  In a second analysis that included the 105 
infants who received a test, the authors reported that mothers who received cART brought their 
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infant for a test 2.63 (95% CL, 0.26-5.00) months later than women who did not receive cART.  
Although the study provides preliminary evidence for an association between providing mothers 
with cART and retention of their exposed infants, a more appropriate methodological approach 
and a larger sample size would provide more accurate and precise results, respectively.  In the 
first analysis, the authors used logistic regression without a clearly defined risk period that did 
not incorporate the longitudinal nature of their data.  By excluding infants who never received a 
test from their second analysis, the authors limited the interpretation of their finding.  A 
comparison of Kaplan-Meier estimates of time to first PCR test for the entire study population 
(including those who never received a test) would have been more informative.  
A second study that included 1587 HIV-exposed infants in Cameroon, examined the 
association between multiple predictors and having an incomplete EID process (a complete EID 
process was defined as receiving a DNA PCR test and returning to receive the result) by seven 
months of age [60].  Controlling for clinical site, maternal education, time since maternal HIV 
diagnosis, mode of delivery, and multiple birth status, the authors found that women who 
received no prophylaxis or a short-course prophylaxis were more likely to have an incomplete 
EID process compared to women who received cART (OR [95% CL] 2.3 (1.2-4.1) and 1.4 (0.9-
2.1) for “No prophylaxis” and “Short-course prophylaxis” versus “cART,” respectively).  
Although this study provides additional evidence for an association between maternal cART and 
retention of HIV-exposed infants from a large study population, the authors used logistic 




Section 2.8.  Motivation for the dissertation project 
Moreover, the body of literature on outcomes of HIV-exposed infants and our 
understanding of what drives those outcomes has increased substantially over the past decade.  
With each new discovery, new guidelines for care are developed.  HIV program implementers 
strive to adopt new guidelines as they become available and to provide the best care they can for 
HIV-exposed infants. However, changes in the standard of care have been substantial and 
shifting away from old practices to implement new recommendations is typically an extensive 
process.  Implementation in resource-deprived settings is particularly challenging, as generally 
clinics are understaffed, workforces are inadequately trained, resources are severely limited, and 
information systems are poor.  Implementation fidelity, or the extent to which interventions are 
implemented as intended by those who designed them, can act as an important mediator of the 
relationship between a program and its intended outcomes [61].  For this reason and to inform 
future scale-up of priority program interventions, it is thus imperative to understand past 
implementation successes and challenges.  Although many current PMTCT interventions are 
known to improve outcomes of HIV-exposed infants in trial settings, there is still a substantial 
gap in our understanding about how HIV program implementers have been able to improve 
outcomes of HIV-exposed infants in field settings.  The purpose of Aim 1 was to fill this gap in 
the literature by describing how key clinical and programmatic outcomes of HIV-exposed infants 
have changed over time in a real world setting in Kinshasa.   
As discussed in more detail above, one outcome of HIV-exposed infants that has been 
particularly challenging to improve has been retention in care of HIV-exposed infants. There is 
evidence indicating that adults on cART have better retention than adults not yet on cART.  Prior 
studies also suggest that providing mothers with cART improves EID among their HIV-exposed 
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infants.  Since HIV-exposed infants are dependent on their caregivers to bring them for clinic 
visits, we hypothesized that providing caregivers with cART could also improve retention of 
their HIV-exposed infants.  Specifically, the goal of Aim 2 was to quantify the effect of 
providing cART to HIV-infected mothers on reducing LTFU among their HIV-exposed infants.  
Whether or not programs should provide cART to all HIV-infected mothers regardless of 
previously established eligibility criteria is an important debate that is occurring right now.  The 
results of Aim 2 could highlight an important collateral benefit countries should consider when 
deciding which strategy to adopt.  
There has been substantial progress in the research of HIV-exposed infants and the 
factors that affect their care.  However, continued efforts are needed.  By addressing the two 
project aims, we hope to better understand the impact PMTCT programs are having on HIV-
exposed infant outcomes and to identify one strategy that could be implemented to improve 
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CHAPTER 3:  METHODS 
 
Section 3.1.  Overview of study design 
We conducted a cohort study of prospectively collected clinical data.  The observational 
design allowed us to evaluate the implementation and outcomes of HIV-exposed infant care, as 
well as the effect of maternal cART on retention of HIV-exposed infants under real-world 
conditions.  A randomized study design would not have been appropriate in this situation, as 
established PMTCT guidelines made it unethical to randomize the intervention that was assessed 
in Aim 2.  Compared to a randomized design, the observational nature of the study also increased 
the generalizability of the results to similar programmatic settings.  As described in more detail 
below, the measurements that were considered in this study were routinely collected and entered 
into a clinical database.  Therefore, a cohort study that utilized information on the entire clinic 
population was as feasible and cost-effective as a case-control study that would have utilized 
only a sample of this information.  Utilizing all available information likely increased the 
precision of study estimates. 
 
Section 3.2.  Study setting/population 
The data used for this study came from an ongoing clinical cohort of 1,707 HIV-exposed 
infants who received family-centered care in an HIV prevention, care, and treatment program 
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affiliated with UNC between January 1, 2007 and July 30, 2013.  The infants received care at 
one of two centralized sites, Bomoi Healthcare Center and Kalembe Lembe Pediatric Hospital.  
January 2007 corresponds approximately to the point in time when HIV-exposed infants became 
eligible for enrollment in the UNC-DRC program as index patients.  
 
Program background   
The UNC-DRC program began in 2003 as a partnership between UNC, the Kinshasa 
School of Public Health and the DRC National Acquired Immune Deficiency Syndrome (AIDS) 
Program to scale-up HIV prevention, care, and treatment programming in the DRC.  By the close 
of the UNC-DRC program at the end of July 2013, the program in Kinshasa consisted of a 
network of 90 maternities providing PMTCT services, 32 tuberculosis (TB) clinics providing 
HIV voluntary testing and counseling, and one primary health center and one pediatric hospital 
providing family-centered comprehensive HIV/AIDS prevention, care, and treatment services. 
The program was designed to identify patients through the increased use of HIV testing in 
PMTCT, TB, routine, and pediatric care, and then link them to a full continuum of services, 
including counseling, testing, and treatment for family members, nutritional and psychosocial 
support, and treatment of HIV disease and opportunistic infections.  
The UNC-DRC program attempted to provide care for HIV-exposed infants in 
accordance with WHO or national guidelines and updated its clinical protocol at least yearly (the 
evolution of these guidelines is described in more detail in Chapter 4).  However, due to 
logistical challenges, implementation sometimes lagged behind protocol updates.  The UNC-
DRC protocol included routine HIV virological testing for HIV-exposed infants over the entire 
2007-2013 follow-up period, with initial testing at six weeks of age and repeat testing at nine 
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months of age.  All positive results were supposed to be confirmed by virological testing on a 
second specimen.  However, until the end of 2009, HIV ribonucleic acid (RNA) assays were the 
only HIV virological tests available at the national laboratory in Kinshasa and stock outs were 
frequent.  Processing of HIV DNA PCRs was implemented at the national laboratory in 
November 2009, by which time the availability of virological tests had become more or less 
stable.  Dried blood spots were intermittently collected before November 2009 in hopes that 
testing by DNA PCR would soon be available and occasionally stored samples were sent to 
national laboratories in other countries for analysis; however, results were rarely available for 
clinical decision-making before HIV infection could be confirmed by serology. 
Before 2011, all HIV-infected mothers identified at an affiliated maternity and their HIV-
exposed infants were referred for follow-up care at one of the two centralized care and treatment 
sites.  Decentralization of pre-cART follow-up began in April 2011 at four maternities and 
expanded to include all maternities by the end of the year.  In the decentralized model, pregnant 
women who were eligible for cART for their own health and their exposed infants were referred 
to a centralized care and treatment site for follow-up care, including PMTCT services.  Women 
who were not yet eligible for cART had the option of receiving follow-up care for themselves 
and their exposed infants at the level of the maternity.  
In accordance with the DRC national guidelines, HIV-positive pregnant women who 
enrolled into care at a UNC-DRC prevention, care, and treatment site received cART if they 
were eligible for their own health.  Before the implementation of Option A in 2010, mothers who 
were not yet eligible for cART received a PMTCT prophylactic regimen of single-dose NVP.  
Once the national guidelines changed to include Option A, mothers who presented for care 
during pregnancy who were not yet eligible for cART began to receive zidovudine (AZT) 
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prophylaxis from as early as 14-weeks gestation up to seven days postpartum.  However, the 
AZT drug supply was inconsistent and until recently was only offered at centralized care and 
treatment sites.  Furthermore, it takes several weeks for individuals on cART or AZT 
prophylaxis to achieve undetectable viral loads and women in resource-deprived settings such as 
Kinshasa often present for care late in pregnancy or at delivery.  Therefore, some women 
continued to receive a prophylactic regimen of single-dose NVP on its own or in addition to AZT 
even after the national guidelines changed.   
The UNC-DRC program also provided prophylactic regimens to HIV-exposed infants to 
prevent vertical transmission.  Before the national guidelines changed, they received only single-
dose NVP at birth.  Extended NVP was implemented as part of Option A, meaning that exposed 
infants were eligible to receive a daily prophylactic regimen with NVP from birth until six weeks 
after weaning or for six days after birth if they were not breastfed.  Due to challenges in 
implementation, some HIV-infected women or their exposed infants received no prophylactic 
regimen.   
 
Section 3.3.  Inclusion and exclusion criteria 
Per the program protocol, all infants born to HIV-infected women enrolled at one of the 
UNC-DRC affiliated programs or referred from Pre-School Pediatric consult at participating 
maternities were eligible for enrollment at one of the two centralized care and treatment sites.  
Enrollees were classified as ‘HIV-exposed infants’ if they were <18 months of age at the time of 
enrollment and born to a confirmed HIV-infected mother.  The maternal HIV-infection status 
was confirmed in the biological mother or in the infants <18 months of age with a positive HIV 
antibody test.   
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The inclusion criteria were different for each specific aim.  For Aim 1, we started with 
the population of HIV-exposed infants enrolled between January 1, 2007 and July 31, 2012.  
Infants enrolled after 18 months of age and those who could not be linked to a mother also 
receiving care in the UNC-DRC program by the time of infant enrollment were excluded.  For 
Aim 2, we started with the population of HIV-exposed infants enrolled between January 1, 2007 
and December 31, 2011.  Infants enrolled after 18 months of age and infants not linked to a 
mother enrolled in the UNC-DRC program by the time of infant enrollment were excluded, as 
were infants whose mothers were enrolled in the UNC-DRC program before their most recent 
pregnancy.  The rational for limiting Aim 2 to infants whose mothers were newly enrolled into 
care during their most recent pregnancy is that we hypothesized that duration of maternal 
enrollment in care was both an important modifier and confounder of the relationship between 
maternal cART and infant LTFU.      
 
Section 3.4.  Ethical considerations 
Written parental informed consent for the UNC-DRC program was obtained for all 
infants and written informed consent was obtained for all mothers.  All research was approved by 
the Ethics Committee of the Kinshasa School of Public Health and the University of North 
Carolina at Chapel Hill Institutional Review Board.  Published results contain no information 




Section 3.5.  Data collection and quality assurance 
Data collection 
In the UNC-DRC program, patient information was recorded by clinic staff at each visit 
on a simplified patient chart.  After the visit, the simplified charts were given to the on-site data 
entry team and the information was entered into an electronic database, usually on the same day.  
The visit schedule for exposed infants and protocol of scheduled services for each visit is 
described in Table 3.1 below.  Moreover, visits were scheduled to occur every four weeks from 
the first visit at two weeks of age through 18 weeks of age and then every three months 
thereafter.  Additional visits and laboratory tests were scheduled as clinically needed.  The 
database was closed for final analysis at the end of July 2013.  
  
Table 3.1 - Summary of clinic visits for HIV-exposed infants up to 18 months of age. 




















Obtain informed consent X          
Obtain personal, social and 
demographic information 
X          
Assess psychosocial support needs and 
disclosure of mother/family 
X X X X X X X X X  
Counsel mother on medication 
adherence & breastfeeding 
X X X X X X X X X X 
Distribute bed nets to patient and 
household members 
X          
Physical examination X X X X X X X X X X 
Assess weight, length, head 
circumference 
X X X X X X X X X X 
Assess for active TB/STI/malaria/OIs X X X X X X X X X X 
PMTCT prophylaxis X1 X1 X1 X1 X1 X1 X1 X1 X1 X1 
Provide OI prophylaxis  X X X X X X X X x 
Assess toxicity of OI prophylaxis  X X X X X X X X x 
Immunizations  X X X   X  X  
PCR3  X     X    
HIV serology         X X 
Full blood count, differential, total 
lymphocyte count  
 X        X 
Adapted from the UNC-DRC program protocol, Version OCT2011 
1. Protected breastfeeding was recommended for HIV-infected women for the first 12 months of life. When replacement feeding was acceptable, 
feasible, affordable, sustainable and safe, avoidance of all breastfeeding was recommended. In practice, some mothers might have continued to 




Monitoring and evaluation, including an explicit attention to data and service quality, 
were part of the core operations of the UNC-DRC program.  These efforts are worth mentioning 
here because they were the inspiration for Aim 1 of this study and because they facilitated to a 
great extent our ability to assess both aims of this dissertation.  Monitoring and evaluation tools 
can be used to summarize programmatic data to improve delivery of patient service and guide 
implementation efforts.  For monitoring and evaluation tools to be effective, they should 
facilitate the summary of raw data in a meaningful way and the timely dissemination to program 
designers and other stakeholders [1].  
In the UNC-DRC program, routine data and service quality checks were run every two 
weeks in EpiInfo Software by program staff in Kinshasa.  The software also produced an 
automated list of patients who did not receive essential services.  Following the circulation of the 
quality report, each indicator and action list was reviewed by a quality assurance committee at 
both sites and priority improvement efforts were set.  The results of these efforts were 
highlighted in a poster presentation at the AIDS 2012 conference in Washington, DC [2].  
 
Section 3.6.  Analytic approach 
Outcome:  Aim 1 
Aim 1 was a descriptive analysis that examined the impact of program interventions for 
HIV-exposed infants enrolled into the UNC-DRC program between January 1, 2007 and June 
30, 2012.  Among all HIV-exposed infants, we estimated the 18-month cumulative incidences of 
the following outcomes: 
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1) Specimen collection for initial HIV virological testing 
2) Confirmed HIV infection 
3) Death 
4) Loss to follow-up  
In the UNC-DRC program, confirmatory testing of all positive vriological test results was 
performed on a second specimen.  Infants were considered LTFU on their last visit date if they 
did not yet have a confirmed HIV status (positive or negative) and were deactivated from care 
with the reason documented as LTFU or if more than six months passed since they were last seen 
in the clinic.  The cutoff of six months was chosen based on empirical evidence from adult HIV 
treatment programs, which suggests that a cutoff of six months from the last attended clinic visit 
results in the least amount of outcome misclassification [3].  In the UNC-DRC program, infants 
were deactivated for LTFU following three tracking attempts after a missed visit.   
Among HIV-exposed infants with confirmed HIV infection by 18 months of age, we also 
estimated the 24-month cumulative incidence of a fifth outcome: 
5) Initiation of cART 
 
Exposure:  Aim 1   
Aim 1 was primarily a descriptive analysis, thus we did not attempt to assess specific 
exposure-outcome relationships.  To assess the impact of program interventions over time on the 
five outcomes of interest, we compared estimates of the cumulative incidences between calendar 




Covariates:  Aim 1 
To understand how characteristics of the study population changed over time, we also 
described the distributions of infant and maternal age at infant enrollment into care, whether or 
not infants and their mothers received prophylactic drug regimens, breastfeeding status 
(breastfeeding at enrollment or not), infant growth status at enrollment (stunted or not, 
underweight or not), duration of maternal enrollment in HIV care at the time of infant 
enrollment, maternal enrollment status (mother newly enrolled into HIV care during most recent 
pregnancy or not), and maternal cART status (receiving cART by infant enrollment or not).   
There was some missing data on infant growth status.  Therefore, we used the first 
available weight and length/height values measured within a month of enrollment.  Infants were 
considered underweight (stunted) if they had a weight-for-age (height-for-age) Z-score more 
than two standard deviations below the median value for a given age group and sex.  Z-scores 
were derived from the WHO Child Growth Standards [4] using the WHO Anthro software 
(version 3.2.2, January 2011) and macro for SAS.   
We hypothesized that outcomes for infants whose mothers were newly enrolled into care 
during their most recent pregnancy would be different than for infants whose mothers were 
enrolled into care before their most recent pregnancy.  Since the proportion of infants whose 
mothers were previously enrolled into care increased over calendar time, we were concerned that 
any changes we observed could be contributed to this increasing proportion.  We therefore 
decided to stratify the Aim 1 analyses by maternal enrollment status (mother enrolled before 
most recent pregnancy or mother newly enrolled).  This was done for all outcomes except for 
infant cART initiation.  For this outcome, there were too few HIV-infected infants born to 
mothers who were enrolled into care before their most recent pregnancy to stratify on maternal 
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enrollment status.  Because gestational age at enrollment of the mother was not reliably collected 
in the UNC-DRC program and there were no routine quality improvement efforts in place to 
improve assessment and data collection for this variable, we defined “newly enrolled” as being 
enrolled at any time during the nine months before infant birth up to infant enrollment. 
 
Statistical analysis:  Aim 1 
Standard descriptive statistics were used to characterize infants and their mothers at 
infant enrollment into care.  Medians with interquartile ranges (IQRs) were reported for 
continuous variables and counts with proportions for were reported for categorical variables.  
Descriptive statistics were estimated overall and by infant enrollment period.   
For the outcome LTFU, the timescale for analysis was days from enrollment in care and 
infants without a clinic visit beyond the enrollment visit were assigned one day of follow-up.  In 
all other analyses, follow-up time was defined as days from birth.  The rational for using a 
different timescale for the LTFU than was used in the rest of the follow-up analyses is that 
infants cannot be lost from care if they are not first enrolled.  Thus, the natural origin for LTFU 
is enrollment into care.  We also wanted to be able to interpret the timescale for this analysis in a 
way that would allow us to directly answer the question “How long are infants enrolled in care 
before they are LTFU?”. For the other outcomes, the more pressing questions to answer are: “At 
what age are infants tested?”, “At what age are HIV infections being confirmed?”,  “At what age 
are infants dying?”, and “At what age are infants started on cART?”  This is because HIV 
disease progression in young children is very rapid and early mortality is high if HIV-infected 
infants do not initiate cART.   
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Regardless of the timescale used, follow-up concluded when the first of the following 
occurred: the event of interest, a competing event, or censoring [5].  Competing risks arise in 
time-to-event analyses when individuals can experience events that preclude them from ever 
experiencing the event of interest [5].  Competing events varied by analysis and are summarized 
in Table 3.2.    
Table 3.2 - Competing risks for outcomes in Aim 1. 
Outcome  Competing risk(s) Censoring event 
Specimen collection for initial 
virologic HIV test 
Death; Graduation from care; 
Confirmation of HIV-negative 
status by serology 
LTFU; Transfer of care to 
another facility; Administrative 
Confirmed HIV infection Death; Graduation from care LTFU; Transfer of care to 
another facility; Administrative 
Death Graduation from care LTFU; Transfer of care to 
another facility; Administrative 
LTFU Death; Graduation from care Transfer of care to another 
facility; Administrative 
cART initiation Death LTFU; Transfer of care to 
another facility; Administrative 
 
Graduation from care from care was defined as being deactivated from care after a 
confirmed HIV-negative status or transition to ongoing HIV care if an HIV-positive result was 
confirmed.  Administrative censoring occurred on the date the dataset was closed for final 
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analysis (July 31, 2012) or when infants aged-out of the risk period of interest (19 months of age 
in the analyses that included all HIV-exposed infants and 25 months of age in the analysis of 
cART initiation among HIV-infected infants). 
We also conducted two sensitivity analyses to assess the extent to which informative 
censoring may have biased our estimates of the 18-month cumulative incidence of confirmed 
HIV infection.  In the first sensitivity analysis, we determined if extending follow-up to 24 
months changed our estimate of the cumulative incidence of confirmed HIV infection. In the 
second sensitivity analysis, we determined the extreme bounds [6,7] of the cumulative incidence 
function under different assumptions about those who were LTFU.  The upper bound assumed 
all infants who were LTFU were confirmed HIV-positive on the day they were LTFU.  The 
lower bound assumed all infants who were LTFU contributed the full amount of person-time (18 
months) before graduating from care. 
 
Outcome:  Aim 2 
The primary outcome of interest for Aim 2 was being lost from care before confirmation 
of an HIV-positive or HIV-negative status.  In the UNC-DRC program, infants were deactivated 
for LTFU following three tracking attempts after a missed visit.  Infants were considered LTFU 
on their last attended clinic visit date if they were documented as LTFU or if more than six 
months passed since they were last seen in the clinic.  We chose to add a second mechanism by 
which infants could be considered LTFU because the routinely implemented mechanism for 
deactivation LTFU infants often lagged considerably.  The second criteria helped classify infants 
who were likely LTFU but not yet documented as such, helping to avoid outcome 
misclassification.  The cutoff of six months was chosen based on empirical evidence from adult 
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HIV treatment programs, which suggests that a cutoff of six months from the last attended clinic 
visit results in the least amount of outcome misclassification [3].   
 
Exposure:  Aim 2 
The exposure of interest was baseline maternal cART status.  Infants were considered 
“exposed” if their mothers had not yet initiated cART by the time of infant enrollment into care 
and “unexposed” if their mother initiated cART before infant enrollment.  The Directed Acyclic 
Graph (DAG) [8] in Figure 3.1 below further explains how we will assess the exposure.   
 
Figure 3.1 - Directed Acyclic Graph depicting the effect of providing HIV-infected mothers 




Covariates:  Aim 2 
As the DAG analysis in Figure 3.1 suggests, the adjustment set for estimating the effect 
of baseline maternal cART status on infant LTFU includes calendar time, maternal enrollment 
duration, maternal CD4 count, infant growth status, and infant age. Additional detail on these 
covariates and their relationship with the primary exposure and outcome of interest is provided 
below:  
1) Maternal CD4:  In accordance with DRC national guidelines, pregnant and 
breastfeeding women only received cART if they were eligible for their own 
health.  Maternal CD4 count is thus associated with the primary exposure 
(maternal cART status).  Furthermore, we hypothesized that women who feel 
sicker are more likely to return for care and therefore their HIV-exposed 
infants are less likely to be LTFU.  In other words, maternal CD4 count may be 
both 1) a cause of the exposure and 2) a cause of the outcome and should be 
treated as a confounder in analyses of the primary exposure-outcome 
relationship.  This covariate was modeled with Stone and Koo’s additive 
splines constrained to be linear in the tails, with knots at the 5th, 35th, 65th, and 
95th percentiles 16 or categorized with a cut point at 350 (for stratified 
analyses). 
2) Calendar time at infant enrollment into care:  Since the proportion of women 
who received cART increases over calendar time, this covariate is associated 
with the primary exposure (maternal cART status).  Although efforts to reduce 
infant LTFU increased over the course of the UNC-DRC program, it is unclear 
whether the outcome itself improved.  Regardless, other infant outcomes (such 
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as positive infant HIV test results) on the causal path from maternal cART 
status to infant LTFU may have improved over calendar time.  Thus, we treat 
calendar time at infant enrollment as a potential confounder in the Aim 2 
analyses. This covariate was modeled with Stone and Koo’s additive splines 
constrained to be linear in the tails, with knots at the 5th, 35th, 65th, and 95th 
percentiles 16. 
3) Maternal enrollment duration:  The longer mothers are enrolled, the more 
likely they are to initiate cART.  In addition, infants of mothers who are stable 
and in care are less likely to be LTFU than infants of all newly enrolled 
mothers.  Thus, maternal enrollment duration is likely an important confounder 
and modifier of the relationship between maternal cART status and infant 
LTFU.  Based on this assumption, we made two decisions in regards to the 
analysis.  First, we excluded infants whose mothers were enrolled before their 
most recent pregnancy.  Although we would have liked to stratify the primary 
analyses by this covariate (mother previously enrolled or newly enrolled), the 
number of infants of previously enrolled mothers who were LTFU was too 
small to generate stratified estimates.  Even after limiting our analysis to newly 
enrolled mothers, maternal cART status remained associated with maternal 
enrollment duration, with mothers on cART more likely to be enrolled longer 
than mothers not yet initiated on cART.  Therefore, we also adjusted for 
maternal enrollment duration.  This covariate was modeled with Stone and 
Koo’s additive splines constrained to be linear in the tails, with knots at the 5th, 
35th, 65th, and 95th percentiles 16. 
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4) Infant factors:  We hypothesized that infant growth status and infant age at the 
time of enrollment would likely be associated with the primary outcome.  
Although we did not hypothesize that these covariates would be directly 
associated with maternal cART, it is likely that there may be another 
unmeasured factor that affects whether mothers get cART and also infant 
growth and infant enrollment age (for example, socioeconomic status).  As we 
expected the association of these covariates with the outcome to be relatively 
strong, we opted to adjust for them in the analysis.  Both were modeled with 
Stone and Koo’s additive splines constrained to be linear in the tails, with 
knots at the 5th, 35th, 65th, and 95th percentiles 16. 
 
Statistical analysis:  Aim 2 
Descriptive statistics were used to generate the distributions of baseline characteristics of 
the study population overall and by exposure group (maternal cART by infant enrollment or no 
maternal cART by infant enrollment).  For the primary analyses, we conducted competing risk 
analyses described by Fine and Gray [5,9].  First, we estimated the 18-month cumulative 
incidence of LTFU stratified by the primary exposure (maternal cART status) and the baseline 
covariates described in the previous section.  95% confidence intervals were generated for all 
estimates to assess precision.  To quantify the effect of providing HIV-infected mothers with 
cART on LTFU of their HIV-exposed infants, we implemented the subdistribution proportional 
hazards model of Fine and Gray [5,9] using the SAS macro %PSHREG [10].  For comparison, 
we also provided estimates of the cause-specific hazard ratio estimated from traditional Cox 
regression models, which are still more widely implemented in the literature.  Multiple 
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imputation using Markov Chain Monte Carlo simulation was used to impute missing values for 
covariates [11,12].  Five imputed datasets were generated.  The estimates that were generated 
from each model are summarized below: 
1) Unadjusted subdistribution hazard ratio.   
2) Subdistribution hazard ratio adjusted for baseline factors (calendar time, 
maternal CD4 count, maternal enrollment duration, infant WAZ, and infant 
age) and estimated from a model that excluded infants with missing data 
(complete case analysis).   
3) Subdistribution hazard ratio adjusted for baseline factors (calendar time, 
maternal CD4 count, maternal enrollment duration, infant WAZ, and infant 
age) and estimated from a model that used multiple imputation to impute 
missing covariate data.  
4) Unadjusted cause-specific hazard ratio.   
5) Cause-specific hazard ratio adjusted for baseline factors (calendar time, 
maternal CD4 count, maternal enrollment duration, infant WAZ, and infant 
age) and estimated from a model that excluded infants with missing data 
(complete case analysis).   
6) Cause-specific hazard ratio adjusted for baseline factors (calendar time, 
maternal CD4 count, maternal enrollment duration, infant WAZ, and infant 
age) and estimated from a model that used multiple imputation to impute 
missing covariate data.  
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In these analyses, follow-up began at enrollment of the infant and continued until the first 
of the following occurred:  the event of interest (LTFU), a competing event (death or graduation 
from care), or a censoring event (18 months of age or July 31, 2013).  Graduation from care was 
defined as being deactivated from care after confirmation of an HIV-negative status or transfer to 
ongoing HIV care and treatment following confirmation of an HIV-positive status.  All analyses 
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CHAPTER 4:  TEMPORAL CHANGES IN THE OUTCOMES OF HIV-EXPOSED 
INFANTS IN KINSHASA, DR CONGO DURING A PERIOD OF RAPIDLY EVOLVING 
GUIDELINES FOR CARE (2007-2013)  
 
Section 4.1.  Introduction 
Globally, an estimated 1.4 million infants are born to HIV-infected pregnant women each 
year [1].  The guidelines for care of HIV-exposed infants have evolved rapidly in recent years 
and ambitious goals for controlling the pediatric HIV epidemic have been set [2,3].  Although 
the incidence of pediatric HIV is declining [1], we still know little about how programmatic and 
clinical outcomes of HIV-exposed infants have changed over time.   
A major evolution in the care of HIV-exposed infants occurred with the implementation 
of early infant diagnosis (EID) by virological testing, which was first recommended by the 
World Health Organization (WHO) in 2007 [4].  Previously, HIV infection in exposed infants 
could only be confirmed by serology at 18 months of age [5,6].  EID is needed to ensure timely 
combination antiretroviral therapy (cART) initiation.  Without cART, a third of HIV-infected 
infants will die in the first year of life [7–9]. 
Since the scale-up of EID, other parts of the prevention of mother-to child HIV 
transmission (PMTCT) landscape have also evolved rapidly (Figure 4.1) [4,10–15].  Mounting 
evidence on the importance of breastfeeding for preventing HIV-exposed infant mortality [16–
18] led the WHO to increase the recommended breastfeeding period from six months (2006 
recommendation [11]) to at least 12 months (2010 recommendation [13]).  Due to the increased 
risk period for vertical HIV transmission through breastfeeding [19,20], the duration and
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complexity of antiretroviral prophylactic regimens in the 2010 guidelines also increased [12].  
By 2012, the WHO endorsed lifelong cART for all pregnant women [21]. 
Evaluating and reporting outcomes in routine care settings is critical to demonstrate the 
scalability of recommended interventions for PMTCT and to assure quality care is being 
provided [22–24].  One study of 561 infants who received care between 2009 and 2012 in the 
Kilimanjaro Region of Tanzania reported 10% mother-to-child HIV transmission [25], despite 
the provision of prophylactic regimens that were expected to reduce vertical transmission to 
below 5% [12].  Another study of 311 mother-infant pairs in Malawi was able to reduce 
transmission to 3%, but 14% of infants died by 24 months of age [26].  
These examples from the field highlight that, despite best efforts to implement current 
guidelines, PMTCT programs do not always achieve intended outcomes for HIV-exposed 
infants.  Our understanding of the impact that PMTCT programs have had on HIV-exposed 
infant outcomes is incomplete, in part because guidelines often change before the impacts of 
previous guidelines have been assessed.  The goal of this study was to describe how key clinical 
and programmatic outcomes of HIV-exposed infants have changed over time in Kinshasa, 
Democratic Republic of Congo (DRC), under evolving guidelines for care.  Beginning with the 
implementation of HIV-exposed infant care in Kinshasa, we describe temporal trends in the 
timing of EID, HIV transmission, death, and loss to follow-up (LTFU), as well as cART 
initiation among infants identified as HIV-infected.  To our knowledge, this is the first study to 
assess if the implementation of new guidelines has coincided with improvements in these 
outcomes for HIV-exposed infants over time. 
 
Figure 4.1 - Evolution of World Health Organization guidelines for prevention of mother-to-child transmission of HIV. 
 
201320102006/2007
Immunological cART eligibility 
criteria for pregnant and 
breastfeeding women
CD4 cell count <200 10 CD4 cell count <350 12 N/A (all eligible) 15
Maternal PMTCT prophylactic 
regimen for women not yet eligible 
for cART for their own health
Maternal  AZT from 28 weeks 
gestĂƟon unƟů delivery, 
sdNVP + AZT/3TC unƟů 7 days 
ĂŌĞƌdelivery 10
KƉƟon A (AZT from 28 weeks 
gestĂƟon unƟů delivery, 
sdNVP + AZT/3TC unƟů 7 days 
ĂŌĞƌdelivery) or KƉƟon B 
(triple ARV from 14 weeks 
gestĂƟon unƟů 1 week ĂŌĞƌ
bƌĞĂƐƞeeding cesƐĂƟon) 12
N/A (all eligible for cART) 15
Infant PMTCT prophylactic regimen 
if mother not yet eligible for cART
for her own health
sdNVP + AZT from birth unƟů
1 week of age 10
KƉƟon A (NVP daily from 
birth unƟů 1 week ĂŌĞƌ
bƌĞĂƐƞeeding cesƐĂƟon) or
KƉƟon B (NVP daily from 
birth unƟl age 4-6 weeks) 12
Daily NVP from birth unƟů 6 
weeks of age 15
Breastfeeding duration Excusive bƌĞĂƐƞeeding unƟů
at least 6 months of age 11
ConƟnue bƌĞĂƐƞeeding unƟů
at least 12 months of age 13
ConƟnue bƌĞĂƐƞeeding unƟů
at least 12 months of age 15
Immunological cART eligibility 
criteria for infants and children
CD4 cell percentage <25% for 
children <12 months of age, 
<20% for children 12-35 
months of age, and <15% for 
children 36+ months of age 4
All children <24 months of 
eligible for cART; CD4 cell 
count ч750 for children 24-60 
months of age and ч350 for 
children 60+ months of age 14
No criteria for children <60 
months of age (all eligible 
for cART); CD4 cell count 
ч500 for children 60+ 






Section 4.2.  Methods 
Study population 
The data for this study come from a family-centered HIV prevention, care, and treatment 
program implemented at two sites (one primary healthcare center and one pediatric hospital) in 
Kinshasa, with technical assistance provided by the University of North Carolina at Chapel Hill 
(UNC-DRC program).  The two centralized sites provided comprehensive care (including 
PMTCT) to HIV-positive women identified through routine HIV testing at 90 maternities and 
their newborn infants, former patients at 32 tuberculosis clinics, and HIV-positive children, as 
well as HIV-positive first-line family members of these individuals.  Routinely collected data 
from HIV-exposed infants enrolled between January 2007 and June 2012 and their mothers were 
linked to construct a cohort of mother-infant pairs.  Mother-infant linkages were constructed 
using routinely assigned unique patient codes.  Each individual’s record contained their own 
patient code, as well as a list of patient codes for their family members also receiving care in the 
UNC-DRC program.  Infants enrolled after 18 months of age and infants not linked to a mother 
enrolled in the UNC-DRC program by the time of infant enrollment were excluded.  
 
Routine care and clinic procedures 
In accordance with WHO guidelines, the UNC-DRC protocol included EID by 
virological testing over the entire study period, with initial testing at six weeks of age and 
confirmatory virological testing of all positive results performed on a second specimen.  
However, until the end of 2009, HIV RNA assays were the only HIV virological tests available 
at the national laboratory in Kinshasa and stock outs were frequent.  HIV DNA PCR testing was 
implemented in November 2009, by which time the availability of virological tests had 
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stabilized.  Specimens for DNA PCR testing were collected on dried blood spots, which were 
transported to the national laboratory on a daily basis in vehicles provided by the UNC-DRC 
program.  Information on the turnaround time for specimen processing was not available.  All 
HIV testing was provided free of charge.   
PMTCT prophylactic regimens, cART, and breastfeeding support were provided 
according to current WHO guidelines.  Before 2010, the only available PMTCT prophylactic 
regimen for mothers not yet eligible for cART (CD4 cell count >200) and their infants was 
single-dose nevirapine, which was provided according to the 2006 WHO guidelines for programs 
with limited capacity [10].  Mothers were encouraged to exclusively breastfeed for six months 
and then wean rapidly [11].  The “Option A” strategy was implemented in the DRC following 
the release of the 2010 WHO guidelines [12].  Mothers not yet eligible for cART (CD4 cell 
count >350) received zidovudine prophylaxis through pregnancy and peripartum nevirapine with 
a zidovudine-lamivudine “tail” around delivery.  Their infants received extended nevirapine until 
one week after the cessation of breastfeeding.  Mothers were encouraged to continue 
breastfeeding for at least 12 months [13].  
Clinic visits for HIV-exposed infants were scheduled to occur every four weeks from the 
first visit at two weeks of age through 18 weeks of age and then every three months thereafter.  
Infants <18 months of age were deactivated from care following a negative HIV virological or 
serological test result obtained more than three months after the cessation of breastfeeding.  
Infants 18 months of age or older were deactivated from care following the cessation of 
breastfeeding and a negative serological test. HIV-infected infants were eligible to receive 
lifelong care and treatment in the UNC-DRC program.  In 2007, infants <18 months of age with 
a CD4 cell percentage <20, infants 18-24 months of age with a CD4 cell percentage <15, and all 
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infants with a WHO clinical stage 3 or 4 were eligible for cART [4].  Between 2008 and 2010, 
infants 12-24 months of age with a CD4 cell percentage <20 and all infants <12 months of age of 
were eligible to receive cART [27].  Starting in 2010, all infants <24 months of age were eligible 
for cART [14]. 
 
Definitions and statistical analysis 
Demographics of infants and their mothers at infant enrollment were characterized using 
standard descriptive statistics. Infants were considered underweight or stunted if they had a 
weight-for-age or height-for-age Z-score more than two standard deviations below the median 
value for a given age group and sex.  Z-scores were derived from the WHO Child Growth 
Standards [28] using the WHO Anthro software (version 3.2.2, January 2011) and macro for 
SAS.  Growth status was based on the first available weight and height values measured within a 
month of enrollment.      
Among all HIV-exposed infants, we estimated the 18-month cumulative incidences of 
specimen collection for initial HIV virological testing, confirmed HIV infection, death, and loss 
to follow-up (LTFU). For HIV-exposed infants with confirmed HIV infection, we also estimated 
the 24-month cumulative incidence of cART initiation.  In the LTFU analysis, follow-up time 
was defined as days from enrollment in care and infants without a clinic visit beyond the 
enrollment visit were assigned one day of follow-up.  Infants were considered LTFU on their last 
attended clinic visit date following three failed tracking attempts after a missed appointment or if 
more than six months passed since they were last seen in the clinic.  In all other analyses, follow-
up time was defined as days from birth.  Follow-up concluded when the first of the following 
occurred: the event of interest, a competing event, or censoring [29].  
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Competing risks arise in time-to-event analyses when individuals can experience events 
that preclude them from ever experiencing the event of interest [29].  Our study included 
multiple outcomes of interest, and competing events varied by analysis.   Death was treated as a 
competing event in the analyses of specimen collection for HIV virological testing, confirmed 
HIV infection, LTFU, and cART initiation.  Graduation from care (i.e. deactivation from care 
after a confirmed negative status or transition to lifelong HIV care if positive) was treated as a 
competing event in the analyses of LTFU, confirmed HIV infection, and death.  In the analysis 
of first specimen collection for HIV virological testing, a confirmatory negative diagnosis by 
serology was also treated as a competing event.  LTFU and transfer of care to another facility 
were treated as censoring events.  Administrative censoring occurred on the date the dataset was 
closed for final analysis (August 2013) or when infants aged-out of the risk period of interest (19 
months of age in the analyses that included all HIV-exposed infants and 25 months of age in the 
analysis of cART initiation among HIV-infected infants).   
To assess how infant outcomes changed over time, we compared cumulative incidence 
estimates and 95% confidence limits (CL) between infants enrolled in three time periods (2007-
2008, 2009-2010, and 2011-2012).  A p-value was obtained for Gray’s test for equality of the 
cumulative incidence function [30] using the SAS %CIF macro (version 1.0, March 2012) [31].  
Since all HIV-infected women enrolled in the UNC-DRC program were eligible to receive 
lifelong care, the proportion of infants whose mothers were newly enrolled into care during their 
most recent pregnancy declined over the study period.  Because outcomes among infants whose 
mothers were enrolled into care before their current pregnancy may be different than those 
whose mothers were newly enrolled, we stratified comparisons of the cumulative incidence 
functions by maternal enrollment status (newly enrolled during most recent pregnancy or 
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previously enrolled) for all outcomes except infant cART initiation.  For this outcome, the 
number of HIV-infected infants whose mothers were previously enrolled was too small to allow 
for stratified analyses. 
 
Sensitivity analyses 
To determine the cumulative incidence of HIV transmission in our study population, we 
only counted HIV infections that were confirmed before 19 months of age.  One infant with an 
initial positive test result died before the positive status could be confirmed.  There were 17 
additional infants confirmed positive who were treated as administratively censored.  If it is 
uninformative, administrative censoring should not bias estimates of the cumulative incidence 
[32].  To check this assumption, we compared our original estimate of the 18-month cumulative 
incidence of confirmed HIV infection to the 24-month cumulative incidence.  Extending follow-
up captured 9 additional events that were not observed in the original analysis due to 
administrative censoring.   
We also assessed potential selection bias induced by informative censoring due to LTFU 
by assessing the extreme bounds [32,33] of the overall 18-month cumulative incidence of HIV.  
The upper bound was estimated assuming all infants who were LTFU instead were confirmed 
HIV-positive on the day they were LTFU.  The lower bound was estimated assuming all infants 
who were LTFU were instead confirmed HIV-negative and “graduated” from care at 18 months 
of age.    
Finally, we wanted to know if implementation of PMTCT services differed between the 
two sites included in the study.  To assess for differences, we compared the cumulative incidence 
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functions for each of the outcomes of interest stratified by site of care.  All analyses were 
conducted in SAS 9.3 (SAS Institute, Inc., Cary, North Carolina). 
 
Ethics statement 
Written parental informed consent for the UNC-DRC program was obtained for all 
infants and written informed consent was obtained for all mothers.  All research was approved by 
the Ethics Committee of the Kinshasa School of Public Health and the University of North 
Carolina at Chapel Hill Institutional Review Board. 
 
Section 4.3.  Results 
Study population characteristics 
Among 1908 HIV-exposed infants enrolled during the study period, 1707 were linked to 
a mother receiving care in the UNC-DRC program and included in the analysis.  At enrollment, 
infants were a median of 2.6 weeks of age (interquartile range [IQR]: 2.1-6.4) and almost all 
(90.6%) were breastfeeding (Table 4.1).  336 (20.3%) infants were underweight and 381 (23.1%) 
were stunted at enrollment, with little change over time.  The proportion of infants who failed to 
receive a PMTCT prophylactic regimen declined from 29.7% for infants enrolled in 2007-2008 
to 7.7% for infants enrolled in 2011-2012.   
At infant enrollment, mothers were a median of 31.1 years of age (IQR: 27.0-34.7) and 
had been enrolled in the UNC-DRC program for a median of 94 days (IQR: 23-168) (Table 4.1).  
Overall, 1331 (78.0%) of mothers received a PMTCT prophylactic regimen or cART during their 




Table 4.1 - Characteristics of HIV-exposed infants and their mothers at infant enrollment 
into care, by calendar period, Kinshasa, Democratic Republic of Congo. 
 Year of infant enrollment into care 
 2007-2012 2007-2008 2009-2010 2011-2012 
 (N=1707) (N=335) (N=730) (N=642) 
Infants     
Median age in weeks (IQR) 2.6 (2.1-6.4) 2.9 (2.1-9.7) 2.4 (2.1-6.0) 2.6 (2.1-6.0) 
Gender [N (%)]     
Female 872 (51.1) 175 (52.2) 375 (51.4) 322 (50.2) 
Male 835 (48.9) 160 (47.8) 355 (48.6) 320 (49.8) 
PMTCT regimen [N (%)]     
No 243 (16.7) 76 (29.7) 119 (20.9) 48 (7.7) 
Yes 1210 (83.3) 180 (70.3) 451 (79.1) 579 (92.3) 
Breastfeeding [N (%)]     
No 123 (9.4) 29 (13.1) 58 (13.1) 36 (5.6) 
Yes 1182 (90.6) 193 (86.9) 384 (86.9) 605 (94.4) 
Cotrimoxazole prophylaxis [N 
(%)]     
No 86 (5.0) 19 (5.7) 28 (3.8) 39 (6.1) 
Yes 1621 (95.0) 316 (94.3) 702 (96.2) 603 (93.9) 
Underweight a [N (%)]     
No 1317 (79.7) 248 (79.2) 564 (79.1) 505 (80.5) 
Yes 336 (20.3) 65 (20.8) 149 (20.9) 122 (19.5) 
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 Year of infant enrollment into care 
 2007-2012 2007-2008 2009-2010 2011-2012 
 (N=1707) (N=335) (N=730) (N=642) 
Stunted b [N (%)]     
No 1268 (76.9) 233 (75.6) 545 (76.5) 490 (77.9) 
Yes 381 (23.1) 75 (24.4) 167 (23.5) 139 (22.1) 
Mothers     
Median age in years (IQR) 31 (27-35) 31 (28-35) 31 (27-34) 31 (27-35) 
Median days enrolled (IQR) 94 (23-168) 75 (32-129) 89 (0-154) 117 (23-531) 
Newly enrolled during most 
recent pregnancy [N (%)]     
No 296 (17.3) 20 (6.0) 94 (12.9) 182 (28.3) 
Yes 1411 (82.7) 315 (94.0) 636 (87.1) 460 (71.7) 
PMTCT regimen [N (%)] c     
No 376 (22.0) 76 (22.7) 176 (24.1) 124 (19.3) 
Yes 1331 (78.0) 259 (77.3) 554 (75.9) 518 (80.7) 
cART initiated [N (%)] d     
No 1232 (72.2) 279 (83.3) 563 (77.1) 390 (60.7) 
Yes 475 (27.8) 56 (16.7) 167 (22.9) 252 (39.3) 
Abbreviations: IQR, Interquartile range; PMTCT, prevention of mother-to-child HIV 
transmission; cART, combination antiretroviral therapy.  Covariate totals may not add up to the 
column totals due to missing data. 
a Underweight defined as weight-for-age Z-score ≤-2. 
b Stunted defined as height-for-age Z-score ≤-2. 
c Includes any maternal regimen (described in more detail in the methods section), including 
maternal cART if initiated before delivery. 
d Includes maternal cART initiated before infant enrollment.
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Outcomes of HIV-exposed infants 
The 18-month cumulative incidence of having a specimen collected for initial virological 
HIV testing increased over the study period, with 99% (95% CL: 98, 100%) of infants enrolled 
in 2011-2012 having a specimen collected by 18 months of age (Table 4.2).  Among infants 
whose mothers were newly enrolled into care, the cumulative incidence of specimen collection 
by two months of age was 28% (95% CL: 24, 34%) for infants enrolled in 2007-2008, 49% (95% 
CL: 45, 53%) for infants enrolled in 2009-2010, and 63% (95% CL: 59, 68%) for infants 
enrolled in 2011-2012.   
Among 1411 infants with newly enrolled mothers, 135 infants were confirmed HIV-
positive, 62 died, and 252 were LTFU over 14300 person-months of follow-up (Table 4.2).  The 
18-month cumulative incidence of HIV declined from 16% (95% CL: 11, 22%) for infants 
enrolled in 2007-2008 to 11% (95% CL: 8, 16%) for infants enrolled in 2011-2012 (Table 4.2, 
Figure 4.2) and death declined from 8% (95% CL: 5, 12%) to 3% (95% CL: 2, 5%) (Table 4.2, 
Figure 4.3).  The 18-month cumulative incidence of LTFU did not improve over calendar time, 
with 18-month cumulative incidences ranging from 16% (95% CL: 13, 19%) to 22% (95% CL: 
18, 26%) (Table 4.2, Figure 4.4). 
Among 296 infants whose mothers enrolled before their current pregnancy, seven infants 
were confirmed HIV-positive, 11 died, and 24 were LTFU over 3949 person-months of follow-
up (Table 4.2).  The 18-month cumulative incidence of HIV declined from 5% (95% CL: 0, 
21%) for infants enrolled in 2007-2008 to 1% (95% CL: 0, 3%) for infants enrolled in 2011-2012 
(Table 4.2, Figure 4.2).  Death also declined over calendar time, with 18-month cumulative 
incidences of 5% (95% CL: 0, 21%) for infants enrolled in 2007-2008 and 3% (95% CL: 1, 7%) 
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for infants enrolled in 2011-2012 (Table 4.2, Figure 4.3).  LTFU increased from 0% (95% CL: 0, 
0%) to 9% (95% CL: 5, 14%) (Table 4.2, Figure 4.4). 
	  
 
Table 4.2 - Follow-up of HIV-exposed infants in Kinshasa, Democratic Republic of Congo, by calendar period at infant 
enrollment into care and enrollment status of the mother (newly enrolled during pregnancy or previously enrolled). 
 Overall Newly Enrolled Previously Enrolled 
 2007-08 2009-10 2011-12 2007-08 2009-10 2011-12 2007-08 2009-10 2011-12 
HIV-exposed infants (N) 335 730 642 315 636 460 20 94 182 
First specimen collection           
Person-months  1435 1943 694 1265 1692 483 170 251 211 
N 220 604 612 212 522 435 8 82 177 
18-month cumulative 
incidence (95% CL) 



















Median weeks to 
collection (IQR) a 









(0.1-5.0) (30.7-.) d (3.9-8.6) (3.7-4.9) 
Median age in weeks at 
collection (IQR) b 

















 Overall Newly Enrolled Previously Enrolled 
 2007-08 2009-10 2011-12 2007-08 2009-10 2011-12 2007-08 2009-10 2011-12 
Final outcomes          
Person-months 3425 6446 8378 3227 5459 5614 198 987 2764 
Confirmed HIV (N) 39 67 36 38 62 35 1 5 1 
18-month cumulative 
incidence (95% CL) 



















Death (N) 23 33 17 22 28 12 1 5 5 
18-month cumulative 
incidence (95% CL) 



















LTFU c (N) 59 103 111 59 97 96 0 9 15 
18-month cumulative 
incidence (95% CL) 






















 Overall Newly Enrolled Previously Enrolled 
 2007-08 2009-10 2011-12 2007-08 2009-10 2011-12 2007-08 2009-10 2011-12 
HIV-infected infants (N) 39 67 36       
Person-months  364 387 151       
Died before cART (N) 6 8 1       
LTFU before cART (N) 5 3 1       
cART (N) 21 56 34       
24-month cumulative 
incidence (95% CL) 







      
Median months from 
enrollment to cART (IQR)a 
12.1 4.9 3.8       
(5.0-.) d (3.0-
11.8) 
(1.2-6.3)       
Median age in months at 
cART (IQR)b 





      




a Estimated from the cumulative incidence function using time since enrollment as the time scale. 
b Estimated from the cumulative incidence function using age as the time scale. 
c Individuals were considered lost to follow-up if they were deactivated with the reason documented as lost to follow-up or if they 
were last seen more than six months before the administrative end of the study. 




Figure 4.2 - 18-month cumulative incidence functions of confirmed HIV infection among HIV-exposed infants in Kinshasa, 
Democratic Republic of Congo.   
Mother newly enrolled       Mother previously enrolled 
 
       




* Cumulative incidence functions are plotted by calendar period at infant enrollment into care and enrollment status of the mother 
(enrolled before current pregnancy or newly enrolled).  P-values are for Gray’s Test for equality of the cumulative incidence 
functions.




Figure 4.3 - 18-month cumulative incidence functions of death among HIV-exposed infants in Kinshasa, Democratic Republic 
of Congo.   
Mother newly enrolled       Mother previously enrolled 
 






* Cumulative incidence functions are plotted by calendar period at infant enrollment into care and enrollment status of the mother 
(enrolled before current pregnancy or newly enrolled).  P-values are for Gray’s Test for equality of the cumulative incidence 
functions.




Figure 4.4 - 18-month cumulative incidence functions of loss to follow-up among HIV-exposed infants in Kinshasa, Democratic 
Republic of Congo.   
Mother newly enrolled       Mother previously enrolled 
 






* Cumulative incidence functions are plotted by calendar period at infant enrollment into care and enrollment status of the mother 
(enrolled before current pregnancy or newly enrolled).  P-values are for Gray’s Test for equality of the cumulative incidence 
functions.




cART initiation among HIV-infected infants 
Among the 142 infants with confirmed HIV infection by 18 months of age, the median 
age at enrollment into care was 6.4 weeks (IQR: 2.3-32.0 weeks) and the median age at specimen 
collection for initial virological HIV testing was 17.3 weeks (IQR: 7.3-46.0 weeks).  The 24-
month cumulative incidence of starting cART increased over time, from 61% (95% CL: 43, 
75%) for infants enrolled in 2007-2008 to 97% (95% CL: 82, 100%) for infants enrolled in 2011-
2012 (Table 4.2, Figure 4.5).  The median time between enrollment and cART initiation declined 
from 12.1 to 3.8 months, and the median age at cART initiation decreased from 17.9 to 9.3 
months.  
 
Figure 4.5 - 24-month cumulative incidence function of combination antiretroviral therapy 
initiation among HIV-infected infants in Kinshasa, Democratic Republic of Congo.   
	  
* Cumulative incidence functions are plotted by calendar period at infant enrollment into care.  




Extending follow-up to 24 months of age did not appreciably change the cumulative 
incidence of confirmed HIV compared to the 18-month estimate, suggesting administrative 
censoring was uninformative in the original analysis.  Among infants whose mothers were newly 
enrolled, the 24-month cumulative incidence of HIV was 15% (95% CL: 11, 19%) for infants 
enrolled in 2007-2008, 12% (95% CL: 10, 15%) for infants enrolled in 2009-2010, and 12% 
(95% CL: 9, 16%) for infants enrolled in 2011-2012.  Among infants whose mothers were 
previously enrolled, the 24-month estimate was 5% (95% CL: 0, 21%) for infants enrolled in 
2007-2008, 7% (95% CL: 3, 14%) for infants enrolled in 2009-2010, and 1% (95% CL: 0, 03%) 
for infants enrolled in 2011-2012.  
Our second sensitivity analysis suggested that our estimates of the 18-month cumulative 
incidence of HIV may be susceptible to bias due to LTFU.  Among all infants, the 18-month 
cumulative incidence of HIV was 11% (95% CL: 9, 13%).  Assuming all infants who were 
LTFU were instead confirmed HIV-positive, the estimate was 26% (95% CL: 24, 28%).  
Assuming all LTFU infants were HIV-negative and “graduated” from care at 18 months of age, 
the estimate was 9% (95% CL: 8, 11%). 
There appeared to be some differences in infant outcomes between the two sites included 
in the analysis.  The only differences that were statistically significant (i.e. Gray’s p-value < 
0.05) were specimen collection for HIV virological testing and confirmed HIV infection.   At the 
pediatric hospital, the 18-month cumulative incidence of specimen collection was 82% (95% CI: 
78, 85%) and the 18-month cumulative incidence of HIV was 12% (95% CI: 8, 16%).  At the 
primary care center, the 18-month cumulative incidence of specimen collection was 94% (95% 
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CI: 93, 96%) and the 18-month cumulative incidence of confirmed HIV was 11% (95% CI: 9, 
14%). 
 
Section 4.4.  Discussion 
Our program’s experience in Kinshasa shows that improvements over time can be 
achieved in a routine care setting under evolving guidelines for care.  Among infants whose 
mothers were newly enrolled during their most recent pregnancy, we observed declines in both 
vertical HIV transmission and infant death.  The 18-month cumulative incidence of HIV was 
30% lower among infants enrolled in 2011-2012 than among infants enrolled in 2007-2008. The 
18-month cumulative incidence of death declined by 60%.  Among HIV-infected infants, we also 
observed an increase in the proportion initiating cART, with over 95% of infants enrolled in 
2011-2012 initiating cART by 24 months of age.   
However, despite these achievements, our results also reveal areas for improvement.  
Among infants in the 2011-2012 cohort whose mothers were newly enrolled, the proportion with 
confirmed HIV infection at 18 months of age was still over 10% and our sensitivity analyses 
suggested that this may be an underestimate if those who were LTFU were at higher risk of HIV 
than those who were retained in care.  Effective interventions can reduce transmission to below 
5% in breastfeeding populations [34].  In our study, about 20% of mothers had not received a 
PMTCT prophylactic regimen or cART by delivery.  Furthermore, most HIV-infected infants 
enrolled in 2011-2012 still did not have their positive status confirmed until after nine months of 
age and 21% of all infants died or were LTFU before their HIV status could be determined.  The 
proportion of infants presenting to care in poor health also remained high throughout the study 
period, with about 20% underweight and 20% stunted overall.  
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EID by virological testing did not become consistently available in Kinshasa until about 
halfway through the study period.  An important limitation to our study is that the UNC-DRC 
program did not routinely collect information on how much time passed between specimen 
collection for virological testing and when results became available for clinical decision-making.  
Although the 18-month cumulative incidence of specimen collection increased to almost 100% 
over the study period, many infants failed to have a specimen collected by the 4-6 week target 
[15].  By two months of age, about 40% of infants with newly enrolled mothers still had not had 
a specimen collected.  This figure leaves ample room for improvement, but is substantially 
higher than that reported for the country as a whole – a recent UNAIDS report estimated that 
only 3% of HIV-exposed infants in the DRC received a virological test for HIV by two months 
of age [1].  
Diagnosing HIV in infected infants as early as possible is crucial because up to a third 
may die in the first year of life without cART [7–9,14].  We observed that the median months 
from enrollment in care to cART initiation decreased from 12 months among infants enrolled in 
2007-2008 to 4-5 months for infants enrolled in later periods, likely due to the increased 
availability of EID.  However, half of HIV-infected infants enrolled in 2011-2012 had not 
initiated cART by 9 months of age and over a quarter had not initiated cART by 12 months of 
age.  There are likely several reasons why infants continue to experience delayed cART initiation 
despite the availability of EID.  In our setting, one reason may have been that HIV-infected 
infants enrolled in care later than the population of all HIV-exposed infants.  Although median 
age at enrollment was only three weeks greater, over a quarter of HIV-infected infants enrolled 
in care after 32 weeks of age.   
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The number of studies describing obstacles to EID have increased [35–38], but a recent 
meta-analysis found that only one study traced HIV-infected infants from enrollment in PMTCT 
care to cART initiation [39].  That study, which included 202 HIV-infected infants in Malawi, 
observed that although the delay in cART initiation declined over time, the overall proportion of 
HIV-infected infants initiating cART did not improve [38].  It is crucial that PMTCT programs 
routinely record individual-level information at each step of the test-and-treat cascade and future 
research should assess where and why bottlenecks to the provision of early cART exist.  
Initiating the EID process at birth, particularly for high-risk infants, may also decrease delays in 
cART initiation [40]. 
Research has shown that infant nevirapine, a component of the PMTCT strategies 
Options A, B, and B+, can select non-nucleoside revers transcriptase inhibitor mutations in the 
majority of infants who become infected with HIV despite prophylaxis [41].  Diagnosing HIV in 
infected infants early reduces exposure to nevirapine prophylaxis and thus the potential for HIV 
drug resistance.  Given existing challenges to EID implementation in many settings, future 
studies should assess how HIV drug resistance and other treatment outcomes of HIV-infected 
infants change with the implementation of new PMTCT guidelines. 
Unlike other outcomes assessed in this study, LTFU did not improve over calendar time 
and even appeared to increase among infants whose mothers enrolled in HIV care before their 
current pregnancy (although the increase was not statistically significant).  The new consolidated 
WHO guidelines [15], which recommend interventions to improve program retention, may 
reduce obstacles to continued engagement in care.  The UNC-DRC program increased its efforts 
to track patients who missed appointments over the study period, but it does not appear that these 
efforts led to a reduction in the proportion of infants who were LTFU.  Research suggests that 
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infants are less likely to be retained in care if their caregivers perceive them as healthy and more 
likely to be retained in care if they are identified as HIV-infected [42,43].  Thus, it is possible 
that the implementation of EID and the communication of initial negative test results, as well as 
the implementation of more effective prophylactic regimens, also affected the proportion of 
infants who were LTFU.  In addition, increased tracking efforts likely led to infants being 
classified as LTFU more quickly in later periods than in earlier periods, potentially leading to 
some degree of bias with regards to ascertaining infant mortality or HIV infection status.  
Most of the LTFU we observed occurred in the first six months after infants enrolled, 
with about 5% never returning for a follow-up visit.  A recent meta-analysis that assessed the 
magnitude of LTFU of HIV-exposed infants along the PMTCT cascade also reported high LTFU 
early in follow-up, with 4-75% LTFU by three months of age [44].  Interventions to improve 
retention should be implemented at the first contact.  Point-of-care services may also improve 
retention [45,46]. 
We observed that infants whose mothers were newly enrolled into care generally had 
worse outcomes than infants whose mothers who were already enrolled in care when they 
became pregnant. Retaining mothers in care beyond the pregnancy and postnatal period may 
improve outcomes among subsequent HIV-exposed infants.  As cART has been associated with 
reduced LTFU among HIV-infected adults [47,48], increasing access to lifelong cART for 
pregnant women could facilitate retaining mothers in care. 
It is important to note that the infants included in this study and their mothers received 
PMTCT and cART services at centralized sites providing comprehensive HIV care.  PMTCT 
services may not be delivered as effectively at sites in Kinshasa providing decentralized services 
[49].  The sites in this study provided routine care services, were integrated into the existing 
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healthcare system, and were supervised by the government.  In addition, they served a patient 
population that was likely representative of other patient populations in Kinshasa.  However, 
technical assistance of the caliber provided by the UNC-DRC program is not routinely available 
in most settings.  Quality assurance was an explicit program priority and may have contributed to 
the improvements we observed [50].  
We believe our program’s results are more or less representative of what can be achieved 
by other programs that provide technical assistance to clinics delivering PMTCT services.  
However, specific implementation challenges will likely vary between settings.  Even within our 
own program, we observed differences in some infant outcomes that suggested there were 
differences between the two sites in how effectively EID and other PMTCT services were 
implemented.  It is important that programs assess outcomes disaggregated by clinic in order to 
assure quality improvement activities are appropriately targeted, even if aggregated program 
results are ultimately disseminated.  
Another major evolution in the care of HIV-exposed infants is occurring now with the 
worldwide scale-up of the 2013 WHO guidelines that endorse lifelong cART for all pregnant 
women (Option B+) [15].  Although PMTCT programs should continue to adopt new guidelines 
as they become available, they should also pay close attention to the quality of care provided and 
routinely monitor intended program outcomes.  We observed encouraging improvements in the 
outcomes of HIV-exposed infants in Kinshasa, but there remains abundant progress to be made.  
Modifiable barriers to delivering interventions in routine care settings need to be identified and 





1.  UNAIDS (2013) Global report: UNAIDS report on the global AIDS epidemic 2013. 
UNAIDS. 
2.  UNAIDS (2011) Countdown to zero: Global plan towards the elimination of new HIV 
infections among children by 2015 and keeping their mothers alive (2011-2015). 
UNAIDS. 
3.  World Health Organization and UNICEF (2012) Countdown to 2015: Maternal, neborn 
and child survival: Building a future for women and children: The 2012 Report. World 
Health Organization. 
4.  World Health Organization (2007) Antiretroviral therapy of HIV infection in infants and 
children: Towards universal access: Recommendations for a public health approach 
(2006). World Health Organization. 
5.  Stevens W, Sherman G, Downing R, Parsons LM, Ou CY, et al. (2008) Role of the 
laboratory in ensuring global access to ARV treatment for HIV-infected children: 
consensus statement on the performance of laboratory assays for early infant diagnosis. 
Open AIDS J 2: 17–25. 
6.  Chantry CJ, Cooper ER, Pelton SI, Zorilla C, Hillyer G V, et al. (1995) Seroreversion in 
human immunodeficiency virus-exposed but uninfected infants. Pediatr Infect Dis J 14: 
382–387. 
7.  Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, et al. (2006) Virologic, 
immunologic, and clinical benefits from early combined antiretroviral therapy in infants 
with perinatal HIV-1 infection. AIDS 20: 207–215. 
8.  Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, et al. (2008) 
Early virological suppression with three-class antiretroviral therapy in HIV-infected 
African infants. AIDS 22: 1333–1343. 
9.  Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, et al. (2008) Early antiretroviral 
therapy and mortality among HIV-infected infants. N Engl J Med 359: 2233–2244. 
10.  World Health Organization (2006) Antiretroviral drugs for treating pregnant women and 
preventing HIV infenction in infants: Towards universal access: Recommendations for a 
publid health approach (2006 version). World Health Organization. 
11.  World Health Organization (2007) HIV and infant feeding: Update based on the technical 
consultation held on behalf of the Inter-agency Task Team (IATT) on prevention of HIV 
infection in pregnant women, mothers and their infants (Geneva, 25-27 October 2006). 
World Health Organization. 
	  
 75 
12.  World Health Organization (2010) Antiretroviral drugs for treating pregnant women and 
preventing HIV infection in infants: Recommendations for a public health approach (2010 
Version). World Health Organization. 
13.  World Health Organization (2010) Guidelines on HIV and infant feeding: Principles and 
recommendations for infant feeding in the context of HIV and a summary of evidence 
(2010). World Health Organization. 
14.  World Health Organization (2010) Antiretroviral therapy of HIV infection in infants and 
children: Towards universal access: Recommendations for a public health approach (2010 
revision). World Health Organization. 
15.  World Health Organization (2013) Consolidated guidelines on the use of antiretroviral 
drugs for treating and preventing HIV infection: Recommendations for a public health 
approach (June 2013). World Health Organization. 
16.  Alvarez-Uria G, Midde M, Pakam R, Bachu L, Naik PK (2012) Effect of formula feeding 
and breastfeeding on child growth, infant mortality, and HIV transmission in children born 
to HIV-infected pregnant women who received triple antiretroviral therapy in a resource-
limited setting: Data from an HIV cohort study. ISRN Pediatr 2012: 763591. 
17.  Young SL, Mbuya MN, Chantry CJ, Geubbels EP, Israel-Ballard K, et al. (2011) Current 
knowledge and future research on infant feeding in the context of HIV: basic, clinical, 
behavioral, and programmatic perspectives. Adv Nutr 2: 225–243. 
18.  Coovadia H, Kindra G (2008) Breastfeeding to prevent HIV transmission in infants: 
balancing pros and cons. Curr Opin Infect Dis 21: 11–15. 
19.  Read JS (2003) Human milk, breastfeeding, and transmission of human 
immunodeficiency virus type 1 in the United States. American Academy of Pediatrics 
Committee on Pediatric AIDS. Pediatrics 112: 1196–1205. 
20.  WHO/UNAIDS/UNICEF/UNFPA (2008) HIV transmission through breastfeeding: a 
review of available evidence: 2007 update. World Health Organization. 
21.  World Health Organization (2012) Programmatic update: Use of antiretroviral drugs for 
treating pregnant women and preventing HIV infection in infants: Executive summary. 
World Health Organization. 
22.  Stringer EM, Chi BH, Chintu N, Creek TL, Ekouevi DK, et al. (2008) Monitoring 
effectiveness of programmes to prevent mother-to-child HIV transmission in lower-
income countries. Bull World Heal Organ 86: 57–62. 
23.  Chi BH, Stringer JS a, Moodley D (2013) Antiretroviral drug regimens to prevent mother-
to-child transmission of HIV: a review of scientific, program, and policy advances for 
sub-Saharan Africa. Curr HIV/AIDS Rep 10: 124–133. 
	  
 76 
24.  Chi BH, Adler MR, Bolu O, Mbori-ngacha D, Ekouevi DK, et al. (2012) Progress, 
challenges, and new opportunities for the prevention of mother-to-Child transmission of 
HIV under the US President’s Emergency Plan for AIDS Relief. J Acquir Immune Defic 
Syndr 60: 78–87. 
25.  Mwendo EM, Mtuy TB, Renju J, Rutherford GW, Nondi J, et al. (2014) Effectiveness of 
prevention of mother-to-child HIV transmission programmes in Kilimanjaro region, 
northern Tanzania. Trop Med Int Heal 19: 267–274. Available: 
http://www.ncbi.nlm.nih.gov/pubmed/24386998. Accessed 10 February 2014. 
26.  Giuliano M, Andreotti M, Liotta G, Jere H, Sagno J-B, et al. (2013) Maternal 
antiretroviral therapy for the prevention of mother-to-child transmission of HIV in 
Malawi: maternal and infant outcomes two years after delivery. PLoS One 8: e68950. 
Available: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3716887&tool=pmcentrez&re
ndertype=abstract. Accessed 23 January 2014. 
27.  World Health Organization (2008) Report of the WHO technical reference group, 
paediatric HIV/ART care guideline group meeting. World Health Organization. 
28.  WHO Multicentre Growth Reference Study Group (2006) WHO Child Growth Standards: 
Methods and development: Length/height-for-age, weight-for-age, weight-for-length, 
weight-for-height and body mass index-for-age. Geneva: World Health Organization. 
29.  Lau B, Cole SR, Gange SJ (2009) Competing risk regression models for epidemiologic 
data. Am J Epidemiol 170: 244–256. 
30.  Gray R (1988) A class of K-sample tests for comparing the cumulative incidence of a 
competing risk. Ann Stat 16: 1141–1154. 
31.  Lin G, So Y, Johnston G (2012) Analyzing survival data with competing risks using 
SAS® software. Proceedings of the SAS® Global Forum 2012 Conference. Cary, NC: 
SAS Institute Inc. 
32.  Cole S, Hudgends M (2010) Survival analysis in infectious disease research: Describing 
events in time. AIDS 24: 2423–2431. 
33.  Cain LE, Cole SR, Chmiel JS, Margolick JB, Rinaldo CR, et al. (2006) Effect of highly 
active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV 
seroconverters. Am J Epidemiol 163: 310–315. 
34.  World Health Organization (2010) PMTCT Strategic Vision 2010-2015: Preventing 
mother-to-child transmission of HIV to reach the UNGASS and Millennium Development 
Goals: Moving towards the elimination of paediatric HIV. World Health Organization. 
	  
 77 
35.  Donahue MC, Dube Q, Dow A, Umar E, Van Rie A (2012) “They have already thrown 
away their chicken”: barriers affecting participation by HIV-infected women in care and 
treatment programs for their infants in Blantyre, Malawi. AIDS Care 24: 1233–1239. 
36.  Ciampa PJ, Burlison JR, Blevins M, Sidat M, Moon TD, et al. (2011) Improving retention 
in the early infant diagnosis of HIV program in rural Mozambique by better service 
integration. J Acquir Immune Defic Syndr 58: 115–119. 
37.  Cook RE, Ciampa PJ, Sidat M, Blevins M, Burlison J, et al. (2011) Predictors of 
successful early infant diagnosis of HIV in a rural district hospital in Zambezia, 
Mozambique. J Acquir Immune Defic Syndr 56: e104–9. 
38.  Braun M, Kabue MM, McCollum ED, Ahmed S, Kim M, et al. (2011) Inadequate 
coordination of maternal and infant HIV services detrimentally affects early infant 
diagnosis outcomes in Lilongwe, Malawi. J Acquir Immune Defic Syndr 56: e122–8. 
39.  Wettstein C, Mugglin C, Egger M, Blaser N, Salazar L, et al. (2012) Missed opportunities 
to prevent mother-to-child-transmission in sub-Saharan Africa: Systematic review and 
meta-analysis. AIDS 26: 2361–2373. 
40.  Lilian RR, Kalk E, Technau K-G, Sherman GG (2013) Birth diagnosis of HIV infection in 
infants to reduce infant mortality and monitor for elimination of mother-to-child 
transmission. Pediatr Infect Dis J 32: 1080–1085. Available: 
http://www.ncbi.nlm.nih.gov/pubmed/23574775. Accessed 18 February 2014. 
41.  Paredes R, Marconi VC, Lockman S, Abrams EJ, Kuhn L (2013) Impact of antiretroviral 
drugs in pregnant women and their children in Africa: HIV resistance and treatment 
outcomes. J Infect Dis 207: 93–100. 
42.  Wachira J, Middlestadt SE, Vreeman R, Braitstein P (2012) Factors underlying taking a 
child to HIV care: implications for reducing loss to follow-up among HIV-infected and -
exposed children. SAHARA J 9: 20–29. Available: 
http://www.ncbi.nlm.nih.gov/pubmed/23237018. Accessed 23 January 2014. 
43.  Braitstein P, Katshcke A, Shen C, Sang E, Nyandiko W, et al. (2010) Retention of HIV-
infected and exposed children in a comprehensive HIV clinical care program in Western 
Kenya. Trop Med Int Heal 15: 833–841. 
44.  Sibanda E, Weller I, Hakim J, Cowan F (2013) The magnitude of loss to follow-up of 
HIV-exposed infants along the prevention of mother-to-child HIV transmission continuum 
of care: a systematic review and meta-analysis. AIDS 27: 2787–2797. 
45.  Jani I V, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, et al. (2011) Effect of point-of-care 
CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in 
primary health clinics: an observational cohort study. Lancet 378: 1572–1579. 
	  
 78 
46.  Faal M, Naidoo N, Glencross DK, Venter WDF, Sa FCP, et al. (2011) Providing 
immediate CD4 count results at HIV testing improves ART initiation. J Acquir Immune 
Defic Syndr 58: 54–59. 
47.  Krebs DW, Chi BH, Mulenga Y, Morris M, Cantrell RA, et al. (2008) Community-based 
follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy 
in Lusaka, Zambia. AIDS Care 20: 311–317. 
48.  McGuire M, Munyenyembe T, Szumilin E, Heinzelmann A, Le Paih M, et al. (2010) Vital 
status of pre-ART and ART patients defaulting from care in rural Malawi. Trop Med Int 
Heal 15: 55–62. 
49.  Edmonds A, Thompson D, Okito V, Feinstein L, Kawende B, et al. (2012) PMTCT 
decentralization does not assure optimal service delivery: revelations from successful 
individual-level tracking of HIV-infected mothers and their infants [Abstract THAE0103]. 
19th International AIDS Conference. 
50.  Feinstein L, Chalachala J, Thompson D, Edmonds A, Okitolonda V, et al. (2012) 
Structured monitoring and evaluation activities can improve patient care: encouraging 
results in Kinshasa, Democratic Republic of Congo [Abstract PE134]. 19th International 
AIDS Conference.  
 
	  
	   79 
CHAPTER 5:  PROVIDING COMBINATION ANTIRETROVIRAL THERAPY TO HIV-
INFECTED MOTHERS DECREASES LOSS TO FOLLOW-UP AMONG THEIR HIV-
EXPOSED INFANTS IN KINSHASA, DR CONGO: A COHORT STUDY 
 
Section 5.1.  Introduction 
Although prevention of mother-to-child HIV transmission (PMTCT) programs have been 
scaled up worldwide, an estimated 260,000 children continue to be infected with HIV each year 
[1].  The ongoing pediatric HIV epidemic and associated mortality is driven in part by the 
overwhelming number of HIV-exposed infants who are lost to follow-up (LTFU) from PMTCT 
care [2–10].  A recent meta-analysis of 11 studies conducted in sub-Saharan Africa estimated 
that 34% of HIV-exposed infants are lost from care by three months of age, with some settings 
reporting over 70% LTFU [11].  Despite the availability of antiretroviral regimens that can 
reduce vertical HIV transmission to below five percent [12], only a marginal impact on 
population-level transmission can be achieved if program retention remains low [13].   
At the clinical level, ensuring HIV-exposed infants are retained in care is necessary to 
administer HIV tests, provide prophylactic drug regimens, monitor breastfeeding, and provide 
other services such as vaccinations.  LTFU of HIV-exposed infants also impedes early initiation 
of combination antiretroviral therapy (cART) for HIV-infected infants.  Early cART initiation is 
critical because, without treatment, a third of infants will die within the first year of life and one 
half within two years [14–17].   
Despite the importance of infant retention for increasing the population-level impacts of 
PMTCT interventions, providing clinical interventions, and improving outcomes such as early
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cART initiation for HIV-infected infants, few modifiable risk factors for infant LTFU have been 
identified.  There is evidence that adult patients receiving cART are less likely to be LTFU than 
patients not on cART [18,19].  As HIV-exposed infants are dependent on their caregivers to 
bring them to care, this evidence also suggests that provision of cART to HIV-infected 
caregivers may play a role in the retention of their HIV-exposed infants.  The goal of this study 
was to quantify the effect of maternal cART on LTFU of HIV-exposed infants receiving PMTCT 
care in Kinshasa, Democratic Republic of Congo (DRC).  We hypothesized that HIV-exposed 
infants whose mothers receive cART experience less LTFU than infants whose mothers do not 
receive cART.  
 
Section 5.2.  Methods 
Study population 
We used data from HIV-exposed infants who received care between January 1, 2007 and 
July 31, 2013 in a family-centered HIV prevention, care, and treatment program implemented at 
two sites in Kinshasa affiliated with the University of North Carolina at Chapel Hill (UNC-DRC 
program).  The two centralized sites provided comprehensive care (including PMTCT services) 
to HIV-positive women identified through routine HIV testing and their newborn infants at up to 
90 maternities, former patients at 32 TB clinics, and HIV-positive children, as well as the HIV-
positive first-line family members of these individuals.  Enrollees were classified as ‘exposed 
infants’ if they were <18 months of age at the time of enrollment and did not yet have a 
confirmed HIV-positive diagnosis.  HIV exposure was confirmed by a positive HIV antibody test 
in the mother or in the infant at <18 months of age.   
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We linked routinely collected data from HIV-exposed infants with data from their 
mothers to construct a cohort of mother-infant pairs.  So that all infants could experience the 
entire 18-month follow-up period, we only included infants who were enrolled before January 1, 
2012.  Infants enrolled after 18 months of age and those who could not be matched to a mother 
receiving care in the UNC-DRC program by the time of infant enrollment were excluded.  Since 
duration of maternal enrollment in care may be an important confounder and modifier of the 
relationship between maternal cART status and infant LTFU, we also opted to exclude infants 
whose mothers enrolled in the UNC-DRC program before their most recent pregnancy.  
Clinic visits for HIV-exposed infants were scheduled to occur every four weeks from the 
first visit at two weeks of age through 18 weeks of age and then every three months thereafter, 
with additional visits scheduled as clinically needed.  Infants were considered confirmed HIV-
negative and deactivated from care if they received a negative HIV virologic or serologic test 
result obtained more than three months after the cessation of breastfeeding.  HIV-exposed infants 
diagnosed with HIV were eligible to receive ongoing HIV care and treatment in the UNC-DRC 
program [20,21].  For infants <18 months of age, HIV was diagnosed by virologic testing, with 
initial testing at six weeks of age and confirmatory virologic testing of all positive results 
performed on a second specimen.  DNA PCR assays were implemented in Kinshasa in 
November 2009.  Before that time, HIV RNA assays were the only available virologic HIV test 
and stock outs were frequent.  Additional details on the program background and services 
provided to HIV-exposed infants are published elsewhere [20–22].  
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Definitions and statistical analysis 
Baseline was defined as infant enrollment in the UNC-DRC program and the outcome of 
interest was LTFU before final confirmation of an HIV-positive or -negative status.  Infants were 
considered LTFU on their last attended clinic visit date following three failed tracking attempts 
after a missed appointment or if more than six months passed since they were last seen in the 
clinic.  The cutoff of six months was chosen based on empirical evidence from adult HIV 
treatment programs, which suggests that a cutoff of six months from the last attended clinic visit 
results in the least amount of outcome misclassification [23].  Infants without a follow-up visit 
beyond the enrollment visit were assigned a survival time of one day, as has been done in 
previous studies of LTFU in order to avoid excluding these infants from the analyses entirely 
[24].  
The primary exposure was baseline maternal cART status.  The reference group included 
infants whose mothers initiated lifelong cART on or before the day of infant enrollment.  cART 
was provided in accordance with World Health Organization (WHO) guidelines for pregnant and 
breastfeeding women in effect at the time.  Before 2010, all women with a CD4 cell count <200 
cells/mm3 were eligible to receive cART [25].  In 2010, the immunological cutoff increased to 
350 cells/mm3 [26].  
Demographics of infants and their mothers at infant enrollment were characterized using 
standard descriptive statistics.  Infants were considered underweight if they had a weight-for-age 
Z-score (WAZ) and stunted if they had a height-for-age Z-score (HAZ) more than two standard 
deviations below the median value for a given age group and sex.  Z-scores were derived from 
the WHO Child Growth Standards [27] using the WHO Anthro software (version 3.2.2, January 
2011) and SAS macro.  Growth status was based on the first available weight or height values 
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measured within a month of enrollment.  Maternal CD4 counts were based on the first available 
measurement within three months of infant enrollment. 
Accounting for competing risks [28], the 18-month cumulative incidence of LTFU was 
estimated within strata of maternal cART status and baseline covariates.  To quantify the effect 
of maternal cART on LTFU, we used the SAS macro %PSHREG [29] to implement the 
proportional subdistribution hazards model of Fine and Gray [28,30].  Crude and covariate-
adjusted hazard ratios (HR), as well as corresponding 95% confidence limits (CL), were 
generated.  In these analyses, follow-up began at enrollment of the infant and continued until the 
first of the following occurred:  the event of interest (LTFU), a competing event (death or 
graduation from care), or a censoring event (18 months of age or August 2013).  Graduation 
from care was defined as being deactivated from care after confirmation of an HIV-negative 
status or transfer to ongoing HIV care and treatment following confirmation of an HIV-positive 
status.  Because the Cox proportional hazards model is more widely implemented than the Fine 
and Gray model, we also provide cause-specific HRs estimated from a Cox model for 
comparison to the subdistribution HRs estimated from the Fine and Gray model in the primary 
analysis.  
Potential confounding factors were assessed via a directed acyclic graph [31] and 
included the baseline variables infant age, infant WAZ, maternal age, maternal CD4 count, 
maternal enrollment duration, and time since the beginning of the study (defined as days between 
January 1, 2007 and the date of infant enrollment).  The covariates were modeled with Stone and 
Koo’s additive splines constrained to be linear in the tails, with knots at the 5th, 35th, 65th, and 
95th percentiles [32].  Missing values for covariates were imputed [33] using the sequential 
regression method described by Raghunathan et al. [34] and implemented in the IVEware 0.2 
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software system (Institute for Social Research, University of Michigan, Ann Arbor, Michigan).  
Five imputed datasets were generated.   To assess whether our results were sensitive to 
imputation assumptions, we also conducted a complete case analysis.  A Firth correction [35] 
was applied because of the small number of events that occurred among some subgroups in 




The current PMTCT strategies recommended by the WHO (Options B and B+) imply 
providing cART to all HIV-infected women regardless of previously established immunological 
criteria.  Therefore, it is also important to know whether providing HIV-infected mothers with 
cART reduces LTFU of their HIV-exposed infants regardless of the health status of the mother.  
To inform this question, we secondarily assessed the HR for the effect of maternal cART on 
infant LTFU stratified by maternal CD4 cell count (<350 or 350+) at infant enrollment.    
Our primary hypothesis was that maternal cART would decrease LTFU of HIV-exposed 
infants by increasing retention of their mothers.  To further explore this hypothesis, we 
conducted a secondary analysis to assess LTFU of mothers during the period of infant follow-up.  
We estimated the cumulative incidence of maternal LTFU during the period of infant enrollment, 
as well as the subdistribution hazard ratio for the effect of maternal cART on maternal LTFU.  In 
these analyses, baseline was defined as enrollment of the infant and follow-up continued until the 
event of interest (maternal LTFU), a competing event (death), or a censoring event (end of infant 
follow-up or transfer of care to another facility).   
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Ethics statement 
Written parental informed consent for the UNC-DRC program was obtained for all 
infants and written informed consent was obtained from all mothers.  All research was approved 
by the Ethics Committee of the Kinshasa School of Public Health and the University of North 
Carolina at Chapel Hill Institutional Review Board.  
 
Section 5.3.  Results  
1,736 HIV-exposed infants enrolled into care during the study enrollment period, of 
which 1,318 were included in the analysis after exclusion criteria were applied (Figure 5.1).  
Infants included in the analysis were enrolled at a median age of 2.6 weeks (interquartile range 
[IQR]: 2.1-6.9 weeks), at which time 89% were breastfeeding, 21% were underweight, and 24% 
were stunted (Table 5.1).  1,008 (76%) infants had mothers who had not yet initiated cART by 
infant enrollment (Figure 5.1).   
Mothers were a median age of 31 years (IQR: 27-34 years) and had been enrolled in the 
UNC-DRC program for a median of 72 days (IQR: 0-126 days) at the time of infant enrollment 
(Table 5.1).  The median enrollment duration was longer for mothers who initiated cART by 
infant enrollment than those who had not initiated cART (109 days versus 56 days).  Baseline 
maternal CD4 count also differed between the exposure groups, with a higher proportion of 
mothers who initiated cART having a CD4 cell count <350 cells/mm3 than mothers who had not 
initiated cART (55% versus 30%).  Mothers who initiated cART had been receiving cART for a 
median of 65 days (IQR: 32-102 days) by the time of infant enrollment.   
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Figure 5.1 - Flowchart depicting the study population. 
 
 
Abbreviations:  UNC, University of North Carolina at Chapel Hill; DRC, Democratic Republic 
of Congo; cART, combination antiretroviral therapy.  
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Table 5.1 - Characteristics of HIV-exposed infants and their mothers at infant enrollment 
into care, by maternal combination antiretroviral therapy status, Kinshasa, Democratic 
Republic of Congo. 
  Maternal cART 
(N=310) 




Median infant age in 
weeks (IQR) 
2.3 (2.1, 3.3) 2.7 (2.1, 9.4) 2.6 (2.1, 6.9) 
Calendar year at infant 
enrollment 
   
2007 15 (4.8) 112 (11.1) 127 (9.6) 
2008 30 (9.7) 158 (15.7) 188 (14.3) 
2009 65 (21.0) 279 (27.7) 344 (26.1) 
2010 68 (21.9) 224 (22.2) 292 (22.2) 
2011 132 (42.6) 235 (23.3) 367 (27.8) 
Infant gender [N (%)]    
Female 156 (50.3) 513 (50.9) 669 (50.8) 
Male 154 (49.7) 495 (49.1) 649 (49.2) 
Any PMTCT regimen 
[N (%)] 
   
Yes 307 (99.0) 786 (86.1) 1093 (89.4) 
No 3 (1.0) 127 (13.9) 130 (10.6) 
Breastfeeding    
Yes 222 (90.6) 628 (89.0) 850 (89.4) 
No 23 (9.4) 78 (11.0) 101 (10.6) 
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  Maternal cART 
(N=310) 




Infant underweight    
Yes 57 (19.1) 210 (21.5) 267 (21.0) 
No 241 (80.9) 765 (78.5) 1006 (79.0) 
Infant stunted    
Yes 66 (22.2) 236 (24.3) 302 (23.8) 
No 231 (77.8) 737 (75.7) 968 (76.2) 
Median maternal age in 
years [IQR] 
32 (29-35) 30 (26-34) 31 (27-34) 
Median days mother 
enrolled [IQR] 
109 (74-141) 56 (0-115) 72 (0-126) 
Median days mother on 
cART 
65 (32-102) N/A N/A 
Maternal CD4 count    
<350 cells/mm3 163 (54.9) 278 (29.6) 441 (35.7) 
350+ cells/mm3 134 (45.1) 661 (70.4) 795 (64.3) 
	  
Abbreviations:	  	  cART,	  combination	  antiretroviral	  therapy;	  IQR,	  interquartile	  range;	  PMTCT,	  
prevention	  of	  mother-­‐to-­‐child	  HIV	  transmission	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Overall, 238 infants were LTFU over 13,221 person-months of follow-up and the 18-
month cumulative incidence of LTFU was 19% (95% CL: 16, 21%).  Many infants (5% [95% 
CL: 4, 7%]) never returned for a follow-up visit after enrolling in care, 9% (95% CL: 8, 11%) 
were LTFU within three months, and 13% (95% CL: 11, 15%) were LTFU within six months.  
The 18-month cumulative incidence of LTFU was 9% (95% CL: 6, 13%) among infants whose 
mothers had initiated cART by baseline and 22% (95% CL: 19, 24%) among infants whose 
mothers had not initiated cART by baseline (Gray’s test for equality p-value <0.0001) (Table 
5.2, Figure 5.2).   
An assessment of the 18-month cumulative incidence of LTFU within strata of baseline 
covariates suggested that older infant enrollment age, infant growth stunting, younger maternal 
age, and shorter maternal duration in care were associated with increased LTFU (Table 5.2).  
However, these associations were not statistically significant at an alpha level of 0.05.  There did 
not appear to be differences in the 18-month cumulative incidences of LTFU between strata of 
other covariates, including maternal CD4 cell count.  
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Figure 5.2 - 18-month cumulative incidences of loss to follow-up among HIV-exposed 
infants in Kinshasa, Democratic Republic of Congo, plotted by maternal combination 
antiretroviral therapy (cART) status at infant enrollment into care. 
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Table 5.2 - 18-month cumulative incidence of loss to follow-upa within strata of maternal 
combination antiretroviral therapy status and baseline covariates, Kinshasa, Democratic 
Republic of Congo. 
  Cumulative 
incidence 
95% Confidence limit 
Maternal cART by infant enrollment   
Yes 9.1 (6.2, 12.6) 
No 21.5 (19.0, 24.2) 
Age at infant enrollment    
<4 weeks 17.3 (14.8, 19.9) 
4+ weeks 20.6 (17.0, 24.6) 
Calendar year at infant enrollment    
2007-2008  18.5 (14.4, 23.0) 
2009-2011 18.5 (16.2, 21.0) 
Gender   
Female 19.0 (16.1, 22.1) 
Male 18.0 (15.1, 21.1) 
Breastfeeding   
Yes 18.6 (16.2, 20.9) 
No 17.9 (10.2, 25.7) 
Underweight   
Yes 19.6 (14.8, 24.4) 
No 18.2 (15.8, 20.6) 
Stunted   
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  Cumulative 
incidence 
95% Confidence limit 
Yes 21.1 (16.4, 25.8) 
No 17.7 (15.3, 20.2) 
Age of mother at infant enrollment    
<30 years 20.7 (17.5, 24.0) 
30+ years 16.8 (14.1, 19.6) 
Enrollment duration of mother at 
infant enrollment 
  
<3 months 19.9 (17.2, 22.9) 
3+ months 16.5 (13.5, 19.8) 
Maternal CD4 count at infant 
enrollment 
  
<350 cells/mm3 17.7 (13.9, 21.5) 
350+ cells/mm3 18.9 (16.2, 21.7) 
 
Abbreviations:  cART, combination antiretroviral therapy; PMTCT, prevention of mother-to-
child transmission of HIV 
a Infants were considered LTFU on their last attended clinic visit date following three failed 
tracking attempts after a missed appointment or if more than six months passed since they were 
last seen in the clinic. 
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In the unadjusted Fine and Gray subdistribution hazards model, the HR comparing LTFU 
among infants whose mothers did not receive cART by infant enrollment to those whose mothers 
did receive cART by infant enrollment was 2.48 (95% CL: 1.71, 3.74) (Table 5.3).  Without 
imputing missing data, the covariate-adjusted HR was 3.20 (95% CL: 2.00, 5.33).  After multiple 
imputation was used to account for missing covariate data, the covariate-adjusted HR was 2.76 
(95% CL: 1.79, 4.26).  Using Cox regression, the unadjusted HR was 2.73 (95% CL: 1.88, 4.12), 
the covariate-adjusted HR excluding infants with missing covariate data was 3.27 (95% CL: 
2.05, 5.46), and the covariate-adjusted HR using multiple imputation for missing data was 2.91 
(95% CL: 1.93, 4.56). 
In stratified analyses, we observed a protective effect of providing HIV-infected mothers 
with cART on LTFU of their HIV-exposed infants among both maternal CD4 groups (<350 and 
350+) (Table 5.3).  The effect appeared to be stronger among infants whose mothers had a CD4 
cell count 350 and above (HR: 3.96 [95% CL: 1.73, 9.06]) at the time of infant enrollment 
compared to infants whose mothers had a CD4 cell count below 350 (HR: 2.00 [95%CI: 1.16, 
3.46]), but the difference was not statistically significant. 
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Table 5.3 - Estimated effect of maternal combination antiretroviral therapy on loss to 









Unadjusted Fine and Gray 
model 
    
No maternal cART 210 9426 2.48 (1.71, 3.74) 
Maternal cART 28 3795 1.  
Covariate-adjusted Fine and 
Gray model, complete case b 
    
No maternal cART 175 8616 3.20 (2.00, 5.33) 
Maternal cART 21 3548 1.  
Covariate-adjusted Fine and 
Gray model, multiple 
imputation c 
    
No maternal cART 210 9426 2.76 (1.79, 4.26) 
Maternal cART 28 3795 1.  
Covariate-adjusted Fine and 
Gray model, multiple 
imputation, stratified by 
maternal CD4 d,e 
    
CD4 <350, no maternal cART 60 2230 2.00 (1.16, 3.46) 
CD4 <350, maternal cART 20 1911   
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CD4 350+, no maternal cART 150 7196 3.96 (1.73, 9.06) 
CD4 350+, maternal cART 8 1884   
Abbreviations:  cART, combination antiretroviral therapy; LTFU, loss to follow-up 
a Infants were considered LTFU on their last attended clinic visit date following three failed 
tracking attempts after a missed appointment or if more than six months passed since they were 
last seen in the clinic. 
b Fine and Gray subdistribution proportional hazards model adjusted for baseline variables, 
including infant age, infant WAZ, maternal age, maternal CD4 count, maternal enrollment 
duration, and calendar time. Infants with missing covariate data (N=122) were excluded from the 
analysis. 
c Fine and Gray subdistribution proportional hazards model adjusted for baseline variables, 
including infant age, infant WAZ, maternal age, maternal CD4 count, maternal enrollment 
duration, and calendar time. Missing data were imputed.  
d Fine and Gray subdistribution proportional hazards model adjusted for baseline variables, 
including infant age, infant WAZ, maternal age, maternal enrollment duration, and calendar 
time. Missing data were imputed.  
e Loss to follow-up counts and person-months of follow-up are the average from 5 imputed 
datasets.   
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During the infant follow-up period, the overall cumulative incidence of maternal LTFU 
was 26% (95% CL: 24, 28%).  The cumulative incidence of maternal LTFU was 13% (95% CL: 
10, 17%) among mothers who initiated cART by infant enrollment and 30% (95% CL: 27, 33%) 
among mothers who had not yet started cART by infant enrollment (Gray’s test for equality p-
value <0.0001).  Adjusted for the same baseline factors as in the infant LTFU analysis, the 
subdistribution hazard ratio for the effect of providing HIV-infected mothers on maternal LTFU 
was 2.04 (95% CL: 1.43, 2.91).    
 
Section 5.4.  Discussion  
Although it is clear that LTFU of HIV-exposed infants is an ongoing problem, research 
has yet to identify clear implementation strategies to improve infant retention.  In a large cohort 
of HIV-exposed infants in Kinshasa, DRC, we found that infants whose mothers had not yet 
initiated cART by infant enrollment were more than twice as likely to be LTFU than infants 
whose mothers had initiated cART.  These results suggest that providing cART to HIV-infected 
mothers could lead to improvements in the implementation of PMTCT care for HIV-exposed 
infants, including early infant diagnosis (EID) and timely cART initiation for those that are 
positive.  
To our knowledge, this is the first study to report the cumulative incidence of infant 
LTFU within strata of maternal cART status and the first to provide an estimate of the causal 
effect of maternal cART on LTFU of HIV-exposed infants.  Two prior studies suggested that 
maternal cART is predictive of successful EID of HIV.  The first study, which included 217 
mother-infant pairs from Mozambique, found that mothers who received cART were more likely 
to ever bring their infant for a virological test compared to women who did not receive cART, 
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with an odds ratio of 3.15 (95% CL: 1.02-9.73) controlling for self-reported socio-demographic 
factors [36].  A larger study that included 1,587 HIV-exposed infants in Cameroon examined the 
association between multiple predictors and having an incomplete EID process by seven months 
of age [37].  Controlling for clinical site, maternal education, time since maternal HIV diagnosis, 
mode of delivery, and multiple birth status, the authors found that women who received no 
prophylaxis (OR: 2.3 [95% CL: 1.2-4.1]) or short-course prophylaxis (OR: 1.4 [95% CL: 0.9-
2.1]) were more likely to have an incomplete EID process compared to women who received 
cART. 
While those prior studies provide evidence for an association between maternal cART 
and EID, HIV-exposed infant care involves more than a single testing event due to continued 
exposure to HIV through breastfeeding [38].  Regular follow-up of HIV-exposed infants is 
needed to administer additional HIV tests, communicate test results to caregivers, provide 
prophylactic drugs, and monitor breastfeeding.  An important strength of our study is that we 
assessed attrition through the entire HIV-exposed infant care cascade.  Our findings suggest that 
there is a strong beneficial effect of maternal cART on infant retention and that it persists beyond 
the initial HIV testing event.  We observed that most infants who were LTFU were last seen at 
the clinic in the first six months of infant enrollment.  Other studies have also described high 
rates of LTFU within the first few months [11].  To have the greatest impact on LTFU of HIV-
exposed infants, HIV-infected mothers should be started on cART as early as possible.  
Other strengths of our study are the large sample size, relatively long follow-up time, and 
use of competing risk analyses.  Failure to account for competing risks, which are common in 
longitudinal studies, has been shown to overestimate the risk of experiencing the event of 
interest, particularly when the risk of experiencing the competing event is high [39].  Whether or 
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not providing HIV-infected mothers with cART predicts LTFU of their HIV-exposed infants is a 
function of both the effect of maternal cART on infant LTFU and the effect of maternal cART 
on the competing events (e.g. death) [28].  We chose to use the subdistribution hazards model 
described by Fine and Gray in our primary analysis over a traditional Cox regression model 
because doing so allowed us to interpret the hazard ratio as a measure of risk without the added 
assumption that the event of interest (LTFU) was independent of the competing events (death 
and graduation from care).  Since competing risks are common in routine care settings, we 
consider the subdistribution HR more informative for policy decisions about PMTCT strategies 
than the cause-specific HR from a Cox model.  However, as the distribution of competing events 
may vary between populations, we chose to additionally report cause-specific HRs.  In our study, 
the subdistribution and cause-specific HRs were similar. 
A limitation of our study is that we were only able to estimate the association between 
maternal cART and infant LTFU among infants whose mothers newly enrolled into care.   We 
chose to exclude infants whose mothers were enrolled before their most recent pregnancy 
because we assumed that the effect of providing maternal cART on infant LTFU would be 
different for infants of mothers who were stable and in care compared to the population of 
infants of all newly enrolled mothers.  Although ideally we would have stratified our results by 
maternal enrollment duration (newly versus previously enrolled), the number of events among 
the 225 infants whose mothers were previously enrolled was too few (21 LTFU in 2,894 person-
months of follow-up) to generate stratified estimates.  As having a mother who is stable and in 
care appears to result in low infant LTFU, providing cART to these mothers would not likely 
reduce infant LTFU to the degree observed among infants of all newly enrolled mothers.  
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It is also important to note that the mother-infant pairs in this study received PMTCT 
services at centralized sites providing family-centered comprehensive HIV care.  The effect of 
maternal cART on infant LTFU may not be as strong in settings where infants do not receive 
care at the same site as their mothers.  Although our results are also not directly generalizable to 
programs providing decentralized care, we suspect that a similar reduction in infant LTFU could 
be achieved by providing newly enrolled mothers cART in that setting.  Future studies should 
assess the effect of maternal cART on infant LTFU in decentralized care.  In addition, we 
excluded 116 infants who could not be matched to a mother also receiving care in the UNC-DRC 
program.  Some of these mothers may have been receiving HIV care at a different healthcare 
facility, but it is more likely that most of the excluded infants were orphans. The orphan status of 
HIV-exposed infants should be routinely documented so that research can be conducted on how 
to provide optimal PMTCT care for HIV-exposed infants who may have lost one or more 
caregiver.   
Since DRC was an “Option A” country during the study period, our referent group 
consisted of infants whose mothers were eligible for cART based on established immunologic or 
clinical criteria.  On the other hand, the comparison group primarily consisted of infants whose 
mothers were not yet eligible for cART.  We attempted to address this by controlling for 
maternal CD4 count in the analysis, but residual confounding may remain if there are additional 
differences affecting care-seeking behavior that we did not account for.  We also examined 
stratified effect estimates and saw a strong protective effect of maternal cART on infant LTFU in 
both the low and high maternal CD4 groups.  This suggests that providing HIV-infected mothers 
with cART irrespective of previously established immunological criteria (Options B and B+) 
may also improve infant retention.  Unfortunately, the association between maternal cART and 
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infant retention will be difficult to assess in settings where all mothers receive cART due to the 
lack of a clear comparison group.  Given that most countries have already or are moving towards 
implementing Options B or B+, it is important that we assess the impact that maternal cART has 
on infant outcomes while data are still current from Option A countries.       
Little is known about other factors that contribute to LTFU among HIV-exposed infants.   
There is evidence to suggest that addressing structural barriers including cost, transportation, 
waiting time, and service quality may improve retention in the PMTCT setting [7,36,40–43].  
Addressing issues involving fatalistic attitudes around pediatric HIV and reducing fear of stigma 
and discrimination may also be important [44]. Covariates in this study that appeared to predict 
infant LTFU were older infant enrollment age, infant growth stunting, younger maternal age, and 
maternal enrollment duration.  Estimating the causal effects of these covariates on infant LTFU 
was beyond the scope of this analysis and should be explored in future studies. 
Despite the fact that LTFU of HIV-exposed infants is an ongoing public health problem, 
it remains inadequately studied.  One reason for this is that quality individual-level data from 
HIV-exposed infants are not widely available from field settings.  The UNC-DRC program 
routinely collected prospective individual-level data on HIV-exposed infants and linked data 
between infants and their mothers.  Such linkages are often difficult or impossible to obtain 
retrospectively, limiting the number of studies that are able to construct cohorts of mother-infant 
pairs in order to assess the impact that maternal factors have on infant outcomes.  Routine quality 
improvement activities implemented at the UNC-DRC sites, including active tracking of patients 
who missed clinic appointments, also assured that the data included in the analyses were of high 
quality [45].  It is likely that the active tracking procedures also contributed to the relatively low 
proportions of LTFU we observed.  
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In conclusion, providing HIV-infected mothers with cART could increase retention in 
care of their HIV-exposed infants.  This is an important collateral benefit that countries should 
consider as they make decisions around the provision of cART for all pregnant and breastfeeding 
women (Options B/B+) [46].  As LTFU remains an important barrier to delivering optimal care 
for HIV-exposed infants, explicit interventions to improve retention of HIV-exposed infants 
should be prioritized, particularly in settings where cART is not provided to all mothers.  
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CHAPTER 6:  CONCLUSIONS 
 
 
Section 6.1.  Summary of findings 
We conducted an observational study of mother-infant pairs receiving PMTCT care in a 
comprehensive HIV prevention, care, and treatment program in Kinshasa, DRC between 2007 
and 2013.  There were two aims to the dissertation project.  To fulfill the first aim, we produced 
a manuscript that described temporal changes in the outcomes of HIV-exposed infants since the 
implementation of HIV-exposed infant care in Kinshasa.  To fulfill the second aim, we produced 
a manuscript that assessed the effect of providing cART to HIV-infected mothers on reducing 
LTFU among their HIV-exposed infants.   
For Aim 1, we assessed five primary outcomes among 1707 HIV-exposed infants:  first 
specimen collection for an HIV virologic test, confirmed HIV infection, death, LTFU, and cART 
initiation (HIV-infected infants only).  Overall, we observed encouraging trends.  The proportion 
of infants who had a specimen collected for an HIV virologic test by 18 months of age increased 
from 73% among infants enrolled during the first study period (2007-2008) to 99% among 
infants enrolled in the last study period (2011-2012).  Likewise, the median age at specimen 
collection improved drastically, from 30 weeks among infants enrolled during 2007-2008 to 7 
weeks among infants enrolled during 2011-2012.  We also observed improvements in the 
outcomes confirmed HIV infection and death over time.  The proportion with confirmed HIV 
infection by 18 months of age decreased by half, from 15% infected among those enrolled in the 
first study period to 8% among those enrolled in the last study period.  Death declined from 8% 
 108 
to 3%.  The proportion of HIV-exposed infants who were LTFU did not improve over the study 
enrollment period, hovering between 13-15%.  Although the proportion of HIV-exposed infants 
who were LTFU was relatively low compared to what has been observed in other settings, the 
stagnant trend in this outcome highlights the need for continued efforts to improve retention in 
PMTCT programs.   
For the 129 HIV-infected infants assessed in the analysis, the proportion of infants who 
initiated cART by 24 month of age increased from only 61% to 97%.  The median age at cART 
initiation declined from 18 month to 9 months.  While this is an important improvement, 10 
months is still relatively late for HIV-infected infants to initiate cART.  Additional bottlenecks to 
the provision of early cART need to be identified and addressed.    
We examined trends stratified by maternal enrollment status (enrolled in HIV care prior 
to most recent pregnancy or not) because of hypothesized differences in care-seeking behavior 
between these groups. Overall, we observed few negative outcomes among the group of infants 
whose mothers were enrolled in HIV care before their most recent pregnancy compared to the 
group of infants whose mothers were newly enrolled.  
For Aim 2, we assessed LTFU among 1318 mother infant pairs, a subset of the mother-
infant pairs included in Aim 1.  Overall, 19% of infants were LTFU within 18 months of 
enrolling in care.  We observed that infants whose mothers had not yet initiated cART by infant 
enrollment were more than twice as likely to be LTFU than infants whose mothers had initiated 
cART by infant enrollment.  Accounting for competing risks (i.e. death and graduation from 
care), the 18-month cumulative incidence of LTFU was only 9% among infants whose mothers 
were on cART and 22% among infants whose mothers had not yet initiated cART.  Adjusted for 
infant and maternal factors at baseline, the subdistribution hazard ratio was 2.76 (95% CL: 1.79, 
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4.26).  For both the exposure (no maternal cART) and referent group (maternal cART), we 
observed that most LTFU occurred soon after infant enrollment.  Five percent of infants never 
returned to care after their first clinic visit and 13% of infants were LTFU within the first six 
months.  To have the greatest impact on infant LTFU, HIV-infected mothers should be provided 
with cART as soon as possible.  
 
Section 6.2.  Public health impact 
 
There are several public health messages that the results of this dissertation project point 
to.  A detailed assessment of the public health implications of each aim of the dissertation 
appears in the discussion sections of Chapter 4 (Aim 1) and Chapter 5 (Aim 2).  In this section, 
we synthesize the key public health impacts of the dissertation project.   
 
Aim 1 
In the manuscript “Temporal changes in the outcomes of HIV-exposed infants in 
Kinshasa, DR Congo during a period of rapidly evolving guidelines for care (2007-2013),” we 
analyzed individual-level data on HIV-exposed infants and their mothers to assess changes in 
infant outcomes over time in a family-centered HIV program in Kinshasa, DRC.  During the 
evaluation period (2007-2013), EID was scaled-up and guidelines for PMTCT evolved rapidly – 
the recommended breastfeeding period increased, prophylactic drug regimens became more 
complex, and criteria for initiating cART became more inclusive.  Our results demonstrate that it 
is possible to achieve improvements in the outcomes of HIV-exposed infants over time in field 
conditions, but that high rates of HIV transmission, death, and program attrition, as well as 
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delayed cART initiation and diagnosis of HIV infections, continue despite implementation of 
revised PMTCT guidelines.   
The results of Aim 1 are unique and significant for several reasons.  First, to our 
knowledge, this is the first paper to provide a comprehensive assessment of how programmatic 
and clinical outcomes of HIV-exposed infants have changed over time in a resource-deprived 
setting.  Evaluating and reporting outcomes in field conditions are critical to demonstrate the 
scalability of recommended interventions and to assure that quality care is being provided.  
Although HIV programs have implemented new PMTCT guidelines as they become available 
and the incidence of pediatric HIV is declining, we have little knowledge about the extent to 
which intended program outcomes for HIV-exposed infants have been achieved.  As PMTCT 
programs are gearing up to implement the new 2013 consolidated guidelines [1], our evaluation 
is particularly timely.  
In addition to filling a substantive gap in the literature, Aim 1 was also novel because we 
employed epidemiological methods that appropriately estimated the outcomes of interest in the 
presence of competing risks.  Competing risk analyses are still uncommon in the literature, 
particularly in applied research studies.  Failure to account for competing risks, which are 
common in longitudinal studies, has been shown to substantially bias estimates in many 
instances.  We also provide results from sensitivity analyses to support our main findings.  Thus, 
the manuscript for Aim 1 has clinical, programmatic, and methodological impact as well as local 
and global relevance.   
Aim 2 
In the manuscript “Providing Combination Antiretroviral Therapy to HIV-infected 
Mothers Decreases Loss to Follow-up Among Their HIV-exposed Infants in Kinshasa, DR 
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Congo: A Cohort Study,” we analyzed individual-level data from a large cohort of mother-infant 
pairs who received services for PMTCT in Kinshasa, DRC between 2007 and 2013.  We 
assessed the impact of providing cART to HIV-infected mothers on reducing LTFU among their 
HIV-exposed infants.  Our results demonstrated that infants whose mothers do not receive cART 
are more than twice as likely to be LTFU than infants whose mothers do receive cART.  
The manuscript for Aim 2 is unique and significant for several reasons.  First, to our 
knowledge, this is the first study to report the cumulative incidence of infant LTFU within strata 
of maternal cART status and the first to provide an estimate of the causal effect of maternal 
cART on LTFU of HIV-exposed infants.  The magnitude of LTFU among HIV-exposed infants 
in most PMTCT programs is overwhelming, with some studies reporting over 70% LTFU [2].  
Despite the importance of infant retention for increasing the impact of PMTCT programs, 
opportunities to provide early infant HIV diagnosis, and access to early cART initiation for HIV-
infected infants, few modifiable risk factors for infant LTFU have been identified. Our findings 
suggest that there is a strong beneficial effect of maternal cART on infant retention and that it 
persists beyond the initial HIV testing event. This is an important collateral benefit for countries 
to consider as they decide whether to provide cART for all pregnant and breastfeeding women 
(Options B/B+), as was recently recommended by the World Health Organization [1]. Thus, the 
results of this analysis are particularly timely.  
In addition to filling a substantive gap in the literature, the Aim 2 analysis was also novel 
because we employed epidemiological methods that appropriately estimated the effect of 
maternal cART on infant LTFU in the presence of competing risks (e.g. death).  By accounting 
for competing risks, we did not have to make the assumption that the event of interest (LTFU) 
was independent of the competing events, as is required in order to interpret the hazard ratio 
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from a Cox proportional hazards model as a measure of risk.  Although competing risks are 
common in longitudinal studies, competing risk analyses are still rare in the literature.  This is 
likely because statistical software that readily provides estimates from such analyses are not 
widely available.  We also provide results from sensitivity analyses to support our main findings.  
Thus, like Aim 1, the manuscript for Aim 2 has clinical, programmatic, and methodological 
impact as well as local and global relevance.	  	  
	  
Section 6.3.  Future research directions 
There have been substantial advances in our understanding of outcomes among HIV-
exposed infants in recent years, but continued research efforts are needed.  An important strength 
of our study is that we assessed infant outcomes through the entire HIV-exposed infant care 
cascade.  A recent meta-analysis found that only one study traced HIV-infected infants from 
enrollment in PMTCT care to cART initiation [3].  One reason for this is that quality individual-
level data from HIV-exposed infants is not widely available from field settings.  Even less 
frequently available is information that can be used to link data from infants with data from their 
mothers.   
The limited availability of quality individual-level data from HIV-exposed infants and 
their mothers means that HIV-exposed infant outcomes remain inadequately studied, particularly 
in field settings.  To remedy this, PMTCT programs should be encouraged to routinely record 
individual-level information at each step of the test-and-treat cascade and future research should 
assess if intended program outcomes for HIV-exposed infants are being achieved and where 
bottlenecks to the provision of quality care exist.  Explicit guidelines on how to implement high 
quality routine data collection and monitoring for HIV-exposed infants should be developed.  
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Although implementation research is increasingly being recognized as a priority research area, 
such questions will be difficult to address without first increasing the availability of quality data. 
This study focused on outcomes of HIV-exposed infants receiving family-centered care 
at centralized sites providing comprehensive HIV prevention, care and treatment.  In this regard, 
two future research directions seem particularly important to highlight.  First, given the trend 
towards decentralization of HIV services, it has become increasingly important to understand the 
impact decentralization has on outcomes of HIV-exposed infants.  Second, future research 
should seek to better understand the effect family-centered care (as opposed to care provided at a 
facility different than where other HIV-affected family members are receiving their care) has on 
HIV-exposed infant outcomes.  In our study, we excluded infants who could not be matched to a 
mother also receiving care in the UNC-DRC program.  Some of these mothers may have been 
receiving HIV care at a different healthcare facility, but it is more likely that most of the 
excluded infants were orphans.  More research is need on how to provide optimal PMTCT care 
for HIV-exposed infants who may have lost one or more caregiver.     
Most PMTCT programs struggle to maintain HIV-exposed infants in care through the 
entire exposure period, which depends on breastfeeding cessation and typically lasts until about 
12-24 months of age.  Thus, the follow-up period assessed in this study (18 months) is 
considered “relatively long” by most current standards.  However, HIV exposure is only one of 
many challenges faced by children living in families affected by HIV.  More research is needed 
to describe outcomes of HIV-exposed infants across the life course and to understanding the 
relationship between the unique biological, social, economic, and environmental determinants of 
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